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Abstract 
 
This work explores distinct strategies to overcome phenylketonuria (PKU; OMIM 261600), the 
most common autosomal recessive disorder of amino acid metabolism caused by a deficiency 
of the hepatic human phenylalanine hydroxylase enzyme (hPAH; EC 1.14.16.1) and for which 
the available therapies rely mainly in a dietetic restriction. PKU is considered a conformational 
disease, with loss-of-function, where the normal balance between folding and degradation 
machineries (proteostasis) is displaced towards the accelerated degradation of the misfolded 
hPAH variants due to their decreased stability and high tendency to aggregate. Therefore, 
small molecules modulating either the conformation (pharmacological chaperones, PC) or the 
interaction of misfolded proteins with the cellular pathways involved in protein homeostasis 
(proteostasis regulators; PR) might enhance the concentration and/or location of the target 
proteins thus contributing to alleviate disease pathogenesis. From the more than 600 different 
disease-causing mutations identified to date, the hPAH p.G46S is an excellent model of 
aggregation-prone variants as it promotes self-association and fibril formation in vitro. 
Alternatively, enzyme reposition therapy (ERT) would be an universal therapeutic approach 
as it could rescue the full spectrum of PKU phenotypes. As such, this project aimed to: (i) hint 
a new class of PC, from an in-house compound library, inhibiting hPAH aggregation and using 
p.G46S as the study model; (ii) optimize the experimental conditions for further studies to 
validate PR involved in p.G46S degradation and; (iii) evaluate a potential drug delivery system, 
previously developed by the research group aiming to develop a ERT for PKU. 
By performing in vitro aggregation studies on recombinantly produced p.G46S and 
immunocytochemistry assays on transfected eukaryotic cells, two 3-hydroxyquinolin-2(1H)-
one derivatives (C6 and C18) were identified as aggregation inhibitors. These are promising 
compounds to be used as scaffolds for further structure refinement. Additionally, co-
transfection and co-immunoprecipitation experimental conditions were established in order to 
study the interactions of molecular chaperones and p.G46S, a fundamental step to further 
identify PR. Our assays, regarding the protective effect of chitosan-nanoparticles showed that 
in fact the nanoencapsulated hPAHwt presented a higher activity (after 4 h incubation in 
culture medium, at 37°C) than the naked protein (in the same experimental conditions). 
Overall, the obtained results will allow to continue to pursuit novel therapeutic strategies to 
PKU, which in case of the adaptation of cellular proteostasis approach, might be transversal 
to others conformational disorders. 
 
Key words: Inborn errors of metabolism, Phenylketonuria, Pharmacological Chaperones, 
Proteostasis Regulators, Chitosan Nanoparticles 
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Resumo 
Este trabalho explora diferentes estratégias para tratamento da fenilcetonúria (PKU; OMIM 
261600), o erro hereditário do metabolismo dos aminoácidos mais comum, o qual é causado 
pela deficiência da enzima fenilalanina hidroxilase (hPAH; EC 1.14.16.1) e onde a restrição 
dietética continua a ser a principal abordagem terapêutica. A PKU é considerada uma doença 
conformacional, por loss-of-function da hPAH, em que o balanço normal entre o folding e a 
maquinaria de degradação (proteostase) se encontra deslocado no sentido de acelerar a 
degradação de proteínas misfolded devido à sua instabilidade e tendência para agregação. 
Assim, pequenas moléculas que modulem a conformação (chaperones farmacologócios, PC) 
ou a interação de proteínas misfolded com as vias celulares envolvidas na homeostase 
(reguladores da proteostase; PR) poderão modular a quantidade e/ou localização de 
proteínas alvo e desta forma, contribuírem para melhorar a patogénese da doença. Das mais 
de 600 mutações diferentes, identificadas até à data como causadoras de PKU, a hPAH 
p.G46S é um excelente modelo de variantes associadas a agregação proteica uma vez que, 
in vitro, promove auto-associação e formação de fibrilas. Alternativamente, a terapia 
enzimática de reposição (ERT) seria uma abordagem terapêutica universal, pois poderia 
atuar sobre qualquer fenótipo PKU. Deste modo, este projeto teve como objetivo: (i) 
desenvolver uma nova classe de PC, a partir de uma biblioteca de compostos sintetizados in-
house, com capacidade para inibir a agregação da hPAH, usando a variante p.G46S como 
modelo de estudo; (ii) otimizar as condições experimentais para identificar as vias de 
proteostase envolvidos na degradação da p.G46S de modo a identificar PR e; (iii) avaliar um 
potencial sistema de entrega de fármacos, previamente desenvolvido pelo grupo de 
investigação, que permita alcançar uma abordagem terapêutica para a PKU através de ERT. 
A p.G46S foi produzida em E. coli e os ensaios de agregação permitiram identificar dois 
derivados 3-hydroxyquinolin-2(1H)-one (C6 e C18) inibidores de agregação. Estes resultados 
foram corroborados em ensaios in cellulo, onde os mesmos compostos demonstraram ser 
promissores para serem utilizados como scaffold para refinamento da estrutura molecular. 
Além disso, foram otimizadas as condições experimentais de co-transfeção e co-
imunoprecipitação que permitirão estudar as interações entre chaperones moleculares e a 
p.G46S, um passo fundamental para a futura identificação de PR. Relativamente ao efeito 
protetor das nanoparticulas de quitosano, a proteína hPAHwt nanoencapsulada apresentou 
maior atividade (após 4 h de incubação em meio de cultura, a 37 ° C) do que a proteína livre 
(nas mesmas condições experimentais). 
Em suma, os resultados obtidos com este trabalho permitirão continuar em busca de 
estratégias terapêuticas para a PKU. De realçar que os estudos que envolvam a proteostase 
celular, poderão ser transversais a outras doenças conformacionais. 
Palavras chave: Erros hereditários do metabolismo, Fenilcetonúria, Chaperones 
Farmacológicos, Reguladores da Proteostase, Nanopartículas de quitosano 
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1. NEW APPROACHES TO THE TREATMENT OF INBORN ERRORS OF 
METABOLISM 
The term “inborn error of metabolism” (IEM) was firstly presented by Sir Archibald E. Garrod, 
in 1908 during his studies on alkaptonuria (1) . Since then, the number of diseases identified 
as IEM has increased, due to the development of new diagnostic techniques for the various 
biochemical phenotypes, and, since then, more than five hundred different IEM have been 
described (2).  
Inborn errors of metabolism, or inherited metabolic disorders (IMD), are monogenic disorders 
and classically they result from the lack or impaired activity of a specific enzyme or a transport 
protein. The consequences of the protein deficiency include: (i) accumulation of the enzyme 
substrate, usually present in small amounts; (ii) the deficiency of critical intermediary products; 
(iii) the deficiency of specific final products; (iv) the toxic excess of products of alternative 
metabolic pathways (3). The differences in the phenotypic manifestations observed depend 
on the severity of the underlying gene mutation, the type and function of the affected protein, 
post translation mechanisms, cellular processes, genes in other loci that may also be affected 
and environmental factors. For all these factors,  patients with IMD present a complex 
assembly of symptoms and some IEM are thus considered multifactorial (2). 
IMDs are classified as rare disorders and according to the European Organization for Rare 
Disease (EURODIS), a disease is considered rare when it affects less than 1 in every 2,000 
inhabitants. About 6,000 to 8,000 rare disorders have been described and although the 
individual frequencies are low, collectively IMD affect around 6 to 8% of the EU population (4). 
As stated above, IMDs are inherited in a monogenic or Mendelian form, since only one gene 
plays a predominant role in the determination of disease. The majority of IMDs (67%) are of 
autosomal recessive inheritance, 21% are of autosomal dominant inheritance, while 6% are 
X-linked and another 6% are related with defects in mitochondrial genome. In general, a high 
heterogeneity is observed and the kind and intensity of clinical manifestations are related to 
the type of mutations detected (5). 
As monogenic disorders, IMDs gene mutations can be classified into four major groups: 
missense, nonsense, splicing and frameshift. Missense mutations are typically single 
nucleotide changes that either alter the amino acid in the translated protein or do not alter the 
amino acid (silent mutation). Nonsense mutations are point mutations in a sequence that 
create a premature stop codon (UAA, UAG or UGA) in the coding region of the mRNA, 
resulting in premature translation termination and, usually, a non-functional or rapidly 
degraded protein is expressed. Splicing mutations result in disruption of critical sequences for 
splicing and abolishment of the usual splice sites, or creation of aberrant or cryptic splice sites, 
which in turn resulting in aberrant proteins. Finally, frameshift mutations are commonly caused 
by deletion or insertion of a number of nucleotides that alter the reading frame for any 
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subsequent downstream codons (6). 
According to the pathophysiology, IMDs can be divided into three main categories; (i) 
disorders that give rise to intoxication, (ii) disorders involving energy metabolism and (iii) 
disorders involving complex molecules (7). The first group comprises inborn errors of 
intermediary metabolism since usually they are characterized by an acute or progressive 
intoxication due to a metabolic block and accumulation of toxic compounds. This group also 
includes inborn errors of amino acid catabolism, such as phenylketonuria (7). 
In terms of therapy, the main goal in a IMD is to re-establish the metabolic balance and for 
that, many strategies can be applied either isolated or in combination. The first approach is to 
either decrease the accumulating substrate with diet restriction or to inhibit the  activity of 
enzymes involved in preceding steps of the metabolic pathway. Other common strategies are 
the fast elimination of the toxic products from the body, an increase of the residual enzymatic 
activity (e.g. by cofactor administration) and the supplementation with the reaction end product 
in shortage (8). 
Considering IMD medical care, the treatment represents a significant challenge to the public 
system, even with the scientific achievements of the last years. Until now the majority of the 
available therapies is not definitive and only ameliorates the patient’s symptoms. For these 
reasons, several novel pharmacological treatments are arising and being largely investigated. 
They can be divided into two main groups: mutation specific therapies and non-mutation 
specific therapies. 
1.1. MUTATION SPECIFIC THERAPY 
The existence of a common type of mutations prompted the hypothesis of common type-
specific molecular pathogenesis, in other words, nonsense, splicing and frameshift mutations 
usually lead to loss of or unstable protein whereas missense and in-frame insertion or deletion 
mutations produce nonfunctional or partially functional proteins. The comprehension of the 
underlying molecular mechanism associated with each mutation type led to the development 
of approaches based in the mutations nature, so that a therapeutic strategy developed against 
a certain type of mutation will be effective against similar mutations, regardless the gene (6,9). 
1.1.1. PREMATURE TERMINATION CODON READ-THROUGH THERAPY 
Approximately 1800 inherited human diseases are caused by nonsense mutations thus 
leading to the presence of a premature termination codon (PTC) in the transcript (10). 
Suppressing, by reading through the resulting PTC with compounds, allowing translation to 
continue to the true end of the transcript, is a promising approach for correcting this type of 
mutations (Figure I.1). The read-through compounds reduce ribosome termination at the PTC, 
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resulting in the insertion of a random amino acid and the translation of the remainder of the 
correct full length protein (11). PTCs that occur more than 50 nucleotides upstream of the final 
exon-intron junction generally induce transcript degradation through the nonsense-mediated 
mRNA decay surveillance pathway (12), which make any nonsense mutation that does not 
trigger significant nonsense-mediated mRNA decay a good candidate for this approach. 
 
 
FIGURE I.1. Representation of the termination and readthrough processes. Termination is a 
process that occurs when a ribosome encounters a PTC and the release factors eRF1 and 
eRF3 enter the ribosomal A site to promote translation termination and ribosomal subunits 
dissociation. Readthrough is an alternative process where a near-cognate tRNA forms a less-
than-optimal interaction with a codon decoding the PTC, leading the ribosome to carry on 
translation until reaching the next stop codon. Adapted from (13). 
One of the PTC read-through compounds are aminoglycoside antibiotics. They bind to the 
decoding site of the 16S ribosomal RNA, inducing a local conformational change that allows 
translation through what would otherwise be read as a PTC (14). Paromomycin,  geneticin 
(G418) and gentamicin are aminoglycosides that have demonstrated to partially restore the 
full-length protein of nonsense mutations in mammalian cells (paromomycin and G418) (14) 
and in clinical trials for the treatment of cystic fibrosis, Duchenne muscular dystrophy and 
hemophilia (gentamicin) (15,16). However, for an effective read-through a high concentration 
of aminoglycosides is needed which is often toxic to cells and consequently restricts their uses 
in humans. Furthermore, most antibiotics do not cross the blood-brain barrier efficiently and 
would be of limited use for treating central nervous system diseases. To reduce 
aminoglycosides’ cell toxicity while retaining the read-through activity, some attempts have 
been made in redesign their structure (17).  
The non-aminoglycoside antibiotic PTC124 is a nonsense-suppression read-through 
compound recently identified, that was systemic delivered into mouse models for Duchenne 
muscular dystrophy and cystic fibrosis showing restoration of protein and function in vivo 
without any obvious toxicity (18). PTC124 has demonstrated specific read-through activity to 
the PTC rather than to the true termination codons, promoting selective and specific read-
through of disease-causing premature stop codons (18). Du L et al., have identified more than 
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50 non-aminoglycoside chemicals with read-through activity which may contribute to a rapid 
expansion of the discovery aspect of read-through chemicals (19). 
1.1.2. ANTISENSE OLIGONUCLEOTIDE THERAPY 
Antisense oligonucleotide therapy is based on an antisense oligonucleotide (ASO), which are 
single-stranded deoxyribonucleotides (typically 20 bp in length) that are complementary to the 
target mRNA (20). Hybridization of ASO to the target mRNA via Watson-Crick base pairing 
can result in specific inhibition of gene expression by various mechanisms, depending on the 
chemical make-up of the ASO and location of hybridization, resulting in reduced levels of 
translation of the target transcript. The ASO is not only a useful tool for studies of loss-of-gene 
function and target validation, but also highly valuable as a strategy to treat genetic diseases 
in which decreasing the levels of a mutant protein would favourably alter the phenotype (9). 
ASO induced protein knockdown is usually achieved by induction of RNase H endonuclease 
activity that cleaves the RNA phosphodiester bonds of the RNA–DNA heteroduplex, leading 
to the degradation of target mRNA while leaving the ASO intact (Figure I.2) (21). Another ASO 
mechanism include translational arrest by steric hindrance of ribosomal activity, interference 
with mRNA maturation by inhibiting splicing and destabilization of pre-mRNA in the nucleus 
(22). 
 
FIGURE I.2. Antisense Oligonucleotides Mechanism. (A) Steric hindrance for inhibiting gene 
expression through an antisense oligomer that binds mRNA and blocks translation. (B) 
Binding of a DNA-RNA hybrid oligonucleotide that is recognized by RNase H, which leads to 
the mRNA cleavage. Adapted from (23). 
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Since ASO first use, many chemical modifications have been made to improve resistance to 
nucleases and consequently, to improve their function and to limit their toxicity. One of the 
most successful modifications was the substitution of ribose moieties by a morpholine ring. 
Morpholinos, also known as phosphorodiamidate morpholino oligos (PMOs), normally consist 
of a 25 nucleotides chain with high specificity, water solubility and resistance to a wide range 
of nucleases (24,25). Morpholinos do not freely cross the cells’ membrane, their entry in the 
cell is mediated by endocytosis and need to be aided by a delivery mechanism, either 
electroporation, conjugation with a weakly-basic polyamine (ethoxylated polyethylenimine 
(EPEI)) or the commercially available agent Endo-Porter® (26). Due to this fact, Morpholinos 
cannot be used in in vivo experiments. In order to circumvent this problem, Morpholino 
molecule have been attached to a transporter, resulting in a dendritic structure called vivo-
morpholino that allows an effective cell membrane penetration (27,28). 
Locked nucleic acids (LNAs) are another type of oligonucleotides widely used. In LNAs a 
modified ribonucleotide is used, where the ribose moiety presents an extra bond between the 
2’-oxygen and the 4’-carbon. As such, LNAs present a rigid structure with resemblance with 
RNA, high affinity with complementary RNA as well as ssDNA, high specificity toward the 
target, high stability in vivo, lack of toxicity and good resistance to degradation by 3’-
exonucleases. In addition, it is possible to synthetize oligomers with lower sizes (6 to 20 
nucleotides) and with varied ratios of LNA, allowing different mixtures like LNA/LNA, LNA/DNA 
and LNA/RNA. LNAs act mainly by recruiting RNase H to degrade the aberrant mRNA, 
although non-RNase H based mechanisms have also been reported (29). 
Currently, the ASOs Fomivirsen (Vitravene® from ISIS Pharmaceuticals) have been approved 
for the treatment of cytomegalovirus infection and homozygous familial hypercholesterolemia, 
respectively. Other ASOs are already in phase 2 and 3 of clinical trials (30). These advances 
in antisense therapy are encouraging and contributing to the use of ASO in metabolic 
disorders. 
1.1.3. PHARMACOLOGICAL CHAPERONES AND PROTEOSTASIS 
REGULATORS 
Pharmacological Chaperones (PC) and Proteostasis Regulators (PR) are two classes of 
distinct small molecules that act directly or indirectly to promote the stabilization of 
nonfuncional or partial functional unstable proteins (Figure I.3), originated by specific 
mutations.  
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FIGURE I.3. Influence of pharmacological chaperones (green squares) and proteostasis 
regulators (magenta dots) in protein homeostasis pathways (red arrows). Proteostasis 
regulators can restore protein homeostasis and ameliorate conformational diseases through 
manipulation of proteostasis network, while pharmacological chaperones assist and enhance 
protein folding through a distinct mechanism from the innate biological pathways. Adapated 
from (31). 
 
Pharmacologic chaperones are small molecules which bind to and stabilize intermediate 
folded states of a specific misfolding-prone protein, thereby increasing the concentration of 
native-like states of the mutant protein resulting in increased function or proceed to its 
destination environment to resume its function (32). It is considered a heterogeneous group 
of small compounds as it comprises molecules that bind weakly to a specific target protein, 
competitive inhibitors, ligands, agonists/antagonists and protein cofactors including metal 
ions. Interestingly, interactions with cofactors, either covalent or non-covalent bonds, are 
among those that contribute significantly to the maintenance of the tertiary structure of a 
protein (33). The downside of this approach is the small molecules specificity as they have to 
be tailored for each non-homologous protein linked to a loss-of-function misfolding disease 
(32). Currently, PC have been developed for several inherited metabolic disorders such as 
Gaucher disease (34), infantile Batten disease (35) and Fabry disease (36), which means that 
they have been adopted as a therapeutic strategy to ameliorate protein misfolding diseases. 
When it comes to small molecules to rescue folding defects in proteins, the term chemical 
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chaperone often arises. The slight difference between chemical and pharmacological 
chaperones comes down to the unspecific action for the former and the more specific direct 
action, over a particular target protein, observed in the latter (33). Chemical chaperones are 
mainly osmolytes and include polyols (e.g. glycerol, sorbitol), sugars (e.g. trehalose), 
methylamines (e.g. trimethylamine-N-oxide), free amino acids (glycine, taurin) or its 
derivatives (e.g. ectoine and gama-aminobutyric acid) and also other low molecular weight 
compounds with a chaperone-like function, such as dimethyl sulfoxide (DMSO) (33). As 
mentioned before, chemical chaperones have an unspecific mode of action and do not bind 
directly to proteins, their stabilization action results from the hydration effect which results from 
the ability of water molecules to establish favourable interactions with polar groups from the 
protein backbone, thus increasing protein compactness (37,38). Chemical chaperones had 
shown being effective in rescuing misfolding proteins in diseases such as cystic fibrosis, 
characterized by the impairment of a transmembranar protein (cystic fibrosis membrane 
conductance regulator (39), and also in several mild forms of phenylketonuria (40,41). 
Proteostasis Regulatores act on the machinery responsible for maintaining the cellular protein 
homeostasis (proteostasis) including molecular chaperones among other components. 
Molecular chaperones are defined as any protein that interacts with and aids in the folding or 
assembly of another protein without being part of its final structure (42). They are central 
elements of the proteostasis network (PN), which is considered a fully integrated, layered 
system, unique to each cell type/compartment (43), comprising nearly 1000 molecular 
chaperones. Molecular chaperones regulate protein synthesis, folding, trafficking, 
disaggregation and degradation (32). The PN is used by cells to respond to proteome insults 
through stress sensors and inducible pathways which include the heat shock response (HSR), 
the unfolded protein response (UPR), oxidative stress pathways and growth factor and diet 
sensitive pathways (44–46). For this reason, molecular chaperones are designated as stress 
proteins or heat shock proteins (Hsp) and were initially named according to their molecular 
weight monomers (Hsp40, Hsp60, Hsp70, Hsp90, Hsp110 and small Hsp), although most of 
them exist as oligomers. Based on the sort of interaction with client proteins, molecular 
chaperones are also classified in holdases, foldases, and disaggregases (47). Foldases and 
disaggregases are molecular chaperones that function broadly in de novo folding and refolding 
(i.e. the chaperonins, Hsp70s and Hsp90s). They are ATP regulated and recognize segments 
of exposed hydrophobic amino acid residues, which are later buried in the interior of the 
natively folded protein. Binding to hydrophobic segments enables these chaperones to 
recognize the non-native states of many different proteins. Folding is then promoted during 
ATP- and cochaperone-regulated cycles of binding and release of non-native protein. In this 
mechanism of kinetic partitioning, (re)binding to chaperones blocks aggregation and reduces 
the concentration of free folding intermediates, whereas transient release of bound 
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hydrophobic regions is necessary for folding to proceed. Holdades are ATP-independent 
chaperones (such as the small Hsps) that buffer aggregation. They can recognize and 
stabilize partially folded proteins, preventing their aggregation and presenting client proteins 
to foldases (47–49). 
Because protein molecules are highly dynamic, constant chaperone surveillance is required 
to ensure proteostasis. Recent advances suggest that unbalanced cell proteostasis are in the 
origin of aging and also of pathological states related to a wide range of diseases such as 
oncological diseases, Alzheimer’s, Parkinson’s and metabolic disorders. Presently, the Hsp90 
inhibitor 17-allylaminogeldanamycin (17-AAG) is the first modulator to enter clinical trials (50) 
due to evidences of recent work that identified the molecular chaperone Hsp90 as being 
involved in the stabilization and conformal maturation of many signaling proteins that are 
deregulated in cancers, showing that its inhibition results in the proteosomal degradation of 
these client proteins and consequently leads a possible antitumor activity (51). In addition, 
celastrol and MG-132, heat shock transcription factor 1 (HSF-1) enhancers, have been 
described to increase cytosol’s proteostasis capacity and might induce one or more of the 
three pathways of the unfolded protein response (UPR) that remodels the proteostasis 
network and were stated to be candidates to treat two loss of function diseases (52). 
Hence, while a decline of the PN is detrimental to cell and organismal health, a controlled 
perturbation of this network may offer new therapeutic avenues against human diseases 
(53,54).  
1.2. NON-MUTATION SPECIFIC THERAPY 
The development of strategies where mutation nature is not considered has also showed very 
interesting outcomes in a wide range of genetic diseases, including metabolic disorders, 
neurodegenerative, haematological, immunological and ocular. This type of therapeutic 
approach is considered transversal and effective against different type of genetic diseases, 
for which the gene causing the underlying condition has been identified, regardless how well 
the underlying pathophysiology is understood. Hence, non-mutation specific therapies emerge 
as a promise of providing lasting therapies and even cures for diseases that were previously 
untreatable. 
1.1.1. GENE THERAPY 
Gene therapy is the delivery of genetic material into an individual’s cells and tissues to treat 
inherited or acquired diseases. It is seen as a promising molecular approach that directly 
delivers into the host cell nucleus a gene aimed to repair the genetic defect, in order to cure 
or ameliorate the clinical phenotype (55,56). Although, gene therapy can provide treatment for 
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complex genetic diseases and acquired genetic diseases, its ideal target are monogenic 
diseases (56,57). According to literature, gene therapy has been shown to be effective in 
treating metabolic diseases (58), immune-deficiencies (59,60), eye (61) and coagulation 
disorders (62). These type of disorders are characterized by the dysfunction of a single specific 
gene, where the complete absence or the reduction in activity of the gene product causes the 
pathological phenotype. Thus, the introduction of one or more copies of the healthy gene is 
able to restore the genetic defect (63). 
A number of methods have been stablished to accomplish gene delivery, taking into account 
not only the characteristics of the different genetic diseases, such as the size of therapeutic 
gene to be transferred and the tissue affected, but also several characteristics of what is an 
ideal vector: efficient and specific transduction of the target cell regardless of cell cycle, a 
therapeutic level and proper duration of gene expression, no associated genotoxicity, absent 
pre-existing immunity against the vector and transgene and a non-invasive delivery route (58).  
Effective strategies for clinical gene therapy are based in either in vivo or ex vivo gene delivery 
methods. The in vivo method involves direct introduction of the vector, carrying the therapeutic 
gene, into the patient, either into or near the target organ. Although this procedure might lead 
to inadvertent gene transfer into tissues and cell types that are not proper targets and may 
elicit immune responses towards the transgene and the vector or even damage to healthy 
genes, it may be ideal for metabolic diseases for which liver transplantation is a treatment 
(64). The ex vivo gene therapy implies the isolation of target cells, from donors or patients, to 
be genetically modified in vitro. Cells are harvested and transduced with a vector to express 
the therapeutic gene at normal or even supra-normal levels. Subsequently, to restore the 
healthy phenotype, the gene-corrected cells are infused into the patient where they can 
proliferate (57). This approach is appropriate for tissue specific diseases for which cell 
expansion or transplantation have been stablished as a treatment and for this reason has 
largely been focused on genetic diseases that involved hematopoetic derived cells (65,66). 
Different types of gene delivery systems have been exploited as useful vehicles for gene 
delivery: viral and non-viral vectors. The most common viral vectors are derived from 
pathogenic viruses: retroviruses, lentiviruses, adenoviruses and adeno-associated viruses 
(58). Actually, viral vectors arise from its innate ability of deliver genetic material into infected 
cells. The principles for the generation of viral vectors are the elimination of the viral toxic and 
infective functions, without altering the capacity to efficiently infect cells and deliver new 
transgenes (67).  
Non-viral vectors, when compared with viral vectors, tend to be less immunogenic, to have 
larger packing capacity and easier to be produced. However, the cellular uptake is not very 
efficient. Several strategies, such as the use of polymeric systems and compounds or physical 
delivery methods have been used in order to overcome non-viral vectors limitations. Those 
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efforts may, in the future, result in a shift from the use of viral delivery to the use of non-viral 
delivery, but, in the present, viral delivery is the preferred approach in gene therapy(58). 
In fact, new vectors are constantly under development with the aim of targeted integration and 
DNA editing. At the beginning, early clinical trials for gene therapy were initiated with the hope 
that a new era for the treatment of inherited diseases would begin, but, only more recently, 
gene therapy clinical trials have demonstrated safety and efficacy in treating genetic diseases. 
Gene therapy is certain to represent a new and exciting therapeutic option, when one 
considers that there are no or inadequate treatment for a majority of patients with genetic 
diseases (58). 
1.1.2. ENZYME REPLACEMENT THERAPY 
Enzyme Replacement Therapy (ERT) is a medical treatment to reintroduce an enzyme into a 
patient who has deficiency of a specific enzyme, and is usually associated with inherited 
metabolic diseases. The concept of systemic delivery of an enzyme, to rescue cellular 
function, first started with Lysosomal Storage Diseases (LSD) and it derives from early cell-
culture experiments by Neufeld and her group (63,68). ERT is usually performed by infusions 
of an enzyme that is purified from human or animal tissue or blood or produced by novel 
recombinant techniques. Typically, the enzyme is modified to allow for a longer half-life, more 
potent activity, resistance to degradation or targeting to a specific organ, tissue or cell type 
(69). One of the first successful ERT was for alpha-1-antitrypsin (A1AT) deficiency using 
derived purified human A1AT (70) and the second one was developed for type I Gaucher 
disease, an inherited deficiency of the lysosomal enzyme β-glucocerebrosidase that leads to 
accumulation of the substrate in lysosomes. Initial ERT for Gaucher disease Type I used highly 
purified placenta-derived glucocerebrosidase and later on recombinant technology, 
constituting now the standard therapy for this disease (71). 
Currently, ERT is also available to treat other enzyme deficiency syndromes such as Fabry 
disease, Pompe disease, Hurler and Hunter syndrome, lysosomal acid lipase deficiency and 
several of the rarer forms of mucopolysaccharidoses (69). 
Despite the advances in ERT, several technological constraints limit the use of ERT as protein 
formulation due to the inherent instability of these macromolecules. Besides that, no enzyme 
given intravenously crosses the blood-brain barrier, which makes ERT inappropriate for 
metabolic diseases that affects the brain (72).  
Emerging strategies to mitigate ERT limitations include the use of immune tolerance regimens 
(73), covalent PEG attachment strategies (74), modified targeting procedures or 
complementary therapeutic methods, such as those involving pharmacologic chaperones or 
substrate reducing agents (75,76). 
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2. PHENYLKETONURIA 
Phenylketonuria (PKU; OMIM 211600), the most common inborn error of amino acid 
metabolism, is an autosomal recessive disorder caused by a deficiency of the hepatic human 
phenylalanine hydroxylase enzyme (hPAH; EC 1.14.16.1) (77). PKU was first described by 
Asbjørn Følling, one of the first Norwegian physicians to apply chemical methods to the study 
of medicine (78). Nowadays it is known as a worldwide genetic disease with marked regional 
and ethnic variation in its incidence, with a reported prevalence of 1 in 10,000 live births in 
Caucasians (77).  
The deficiency in hPAH causes high levels of L-phenylalanine (L-Phe) concentration in plasma 
and, if left untreated, this condition is accompanied by progressive mental retardation, 
neurological and behavioral problems due to the neurotoxic effect of hyperphenylalaninemia 
(HPA) (77). To date, more than 600 disease causing mutations have been identified in the 
PAH gene (see PAH Mutation Analysis Consortium database; http://www.pahdb.mcgill.ca/) 
and most of them are associated with PKU (79). 
The discovery of PKU by Dr Asbjørn Følling was an important milestone in medicine as the 
PKU model was, since then, used to link neurological effects to metabolic abnormalities and 
has also been used as a template to shed light on over 200 other IEM (80). 
2.1. METABOLIC PATHWAY AND CLINICAL PHENOTYPE 
The amino acid Phe exists as D and L enantiomers, being L-Phe one of the essential amino 
acid required for protein synthesis in humans, once is not synthesized endogenously (81). 
Dietary intake of L-Phe along with endogenous recycling of amino acid stores are the main 
sources of Phe, whereas, in the cell, the consumption of L-Phe occurs via integration into 
proteins, oxidation to L-Tyrosine (L-Tyr) or conversion into other metabolites (Figure I.4) (80). 
The initial and rate-limiting step in the complete catabolism of L-Phe to CO2 and water is its 
hydroxylation to L-Tyr that occurs mainly in the liver. This reaction is catalysed by the complex 
Phe hydroxylating system, consisting of hPAH, the pterin cofactor (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4), and several enzymes that serve to regenerate BH4 (dihydropteridine 
reductase and 4α-carbinolamine dehydratase) (80). This catabolic pathway accounts for 
approximately 75% or more of the disposal of dietary phenylalanine, which explains the major 
role of hPAH in maintaining L-Phe homeostasis (80). 
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FIGURE I.4. L-Phe metabolism pathways in humans. L-Phe pool results from diet intake and 
from recycling trough endogenous amino acid pools from protein degradation. In the main 
pathway, L-Phe is hydroxylated by phenylalanine hydroxylase in the presence of its cofactor 
BH4 and molecular O2 producing L-Tyr. The alternative metabolism produces various 
metabolites, by decarboxilation or transamination, which are excreted in urine. Adapted from 
(80). 
The benzene ring of L-Phe cannot be ruptured without first being hydroxylated in the para 
position. However, the alanine side-chain of the amino acid can be metabolized in the absence 
of the ring hydroxylation step. This alternative pathway is initiated by transamination or 
descarboxilation of L-Phe to phenylpyruvate or phenylethylamine, respectively, followed by 
conversion of the latter compounds to metabolites such as phenyllactate, phenylacetate and 
o-hydroxyphenylacetate, which are posteriorly excreted in the urine. The alternative pathway 
is relevant only when the cell is not able to hydroxylate the L-Phe ring in the para position (82). 
The compromised activity of hPAH results in the failure to convert the L-Phe into L-Tyr, both 
indispensable aromatic amino acids with a requirement set at 25 mg/kg per day. The hPAH 
deficiency results in high levels of L-Phe and low levels of L-Tyr (83). Consequently, in 
untreated scenery, high levels of circulating L-Phe (HPA) give rise to a spectrum of disorders 
(84). 
Any degree of HPA could be referred as a “phenylketonuric” phenotype and would be a risk 
factor to be managed appropriately. According to the HPA degree, various classification 
schemes have emerged. For example, one proposed by Kayaalp and collaborators (85) uses 
a simple nomenclature where PKU is related to (i) most severe type (classical PKU) which, in 
an untreated state, is associated with plasma L-Phe concentrations higher than 1000 µmol/L 
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and dietary L-Phe tolerance of <500 mg/day; (ii) non-PKU HPA which is associated with 
plasma L-Phe concentrations consistently above normal (>120 µmol/L) but lower than 1000 
µmol/L when an individual is on a normal diet; and (iii) variant mild group where individuals do 
not fit the description for either PKU or non-PKU HPA. Another classification scheme proposed 
by Guldberg and co-workers (86) subdivides PAH deficiency into four categories based on L-
Phe tolerance before the age of 5 years. However, despite the widespread utilization of these 
schemes, the classification is not always straightforward because L-Phe concentrations and 
L-Phe tolerance are not easily and accurately measured in newborn babies. Indeed, some 
authors claim that there may be little value in trying to classify this disorder based on current 
knowledge, as there is no clear clinical application (87).  
Clinically, untreated PKU children with the classical PKU phenotype, show impaired brain 
development. Signs and symptoms include microcephaly, epilepsy, severe intellectual 
disability and behaviour problems. The excretion of excessive L-Phe and its metabolites can 
create body odour and skin conditions such as eczema. The mechanisms by which elevated 
blood L-Phe concentrations disturb cerebral metabolism and cognitive function are not fully 
understood. However, there is a proposed mechanism that includes a potential effect of 
disturbed large neutral amino acid (LNAA; which includes L-Phe, L-tryptophan (L-Trp), L-Tyr, 
L-leucine; L- isoleucine and L-valine) transport from blood to the central nervous system 
(CNS) reflecting the competitive nature of the transporter for LNAA at the blood-brain barrier 
(BBB). The low levels of L-Trp and L-Tyr in the CNS will impact the synthesis of 
neurotransmitters namely serotonin and dopamine (from L-Trp) and epinephrine and 
norepinephrine (from L-Tyr). In addition, affected individuals have a decreased myelin 
formation and protein synthesis. White matter pathology will occur (88) and further problems 
can emerge later in life (89). In the third or fourth decade of life, individuals late- or never-
treated may develop severe behavioral or psychiatric problems such as depression, anxiety 
and phobias (90). 
Early treatment in individuals with PKU prevents severe complications as the ones described 
previously. However, a growing evidence suggests that individuals with strict adherence to 
diet may still have some sequelae and suboptimal cognitive outcome (91). 
2.2. FROM GENE TO PROTEIN 
2.2.1. THE PAH GENE AND PKU GENOTYPES 
The PAH gene spreads over 90 kb and consists of 13 exons (representing 3% of the genomic 
sequence), with introns varying from 1 to 20 kb. It maps to chromosome 12, region 12q23.2. 
Chromosome 12 is particularly rich in disease-associated loci, with 487 loci accounting for 
5.2% of known ‘‘disease genes” (77). The locus for the gene encoding the enzyme hPAH, 
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covers 1.5 Mbp and harbours five other genes of known and unknown function (International 
Human Genome Sequencing Consortium, 2001). The cDNA and full-length genomic 
sequences are both visible online in PAHdb (www.pahdb.mcgill.ca/).  
As mentioned before, hundreds of disease-causing mutations in the PAH gene have been 
identified and registered in the Human PAH Mutation Knowledgebase (hPAHdb; 
www.pahdb.mcgill.ca/) (Scriver et al. 2003) (77). The current spectrum of PKU mutations 
consists of ~60% missense mutations; ~13% of deletions; ~11% of splice mutations; ~6% 
silent mutations; ~5% nonsense mutations and ~2% of insertions (87). Mutations have been 
found in all 13 exons, but the majority are localized in the 3’-half of the gene, namely between 
exon 5 and 12 (92). In addition, repetitive DNA sequences are quite abundant and are now 
seen as causes of previously unidentified large PAH gene deletions and duplications (93), as 
well as, the CpG dinucleotides (n51198), which are potential sites for recurrent mutation in the 
PAH gene (94).  
Although mutations at the human locus affecting hPAH, generally, are the cause of the disease 
PKU or related forms of HPA, approximately 1-2% of HPA results from mutations in genes 
encoding for the enzymes involved in the de novo synthesis of BH4 from guanosine 
triphosphate (GTP) and in the regeneration system of BH4 (94). 
Apparently, the HPA phenotype of the patient is determined by the position and nature of the 
mutation, which interfere with the activity of the PAH enzyme. However genotype-phenotype 
correlations may not be a robust predictor (95), because each individual has a personal 
genome and even those with similar mutant PAH genotypes may not have similar “PKU” 
phenotypes (87). Besides, hPAH, as a homomeric enzyme, exhibit interallelic 
complementation (IC), a phenomenon that occurs in heteroallelic states when particular 
combinations of two different mutant alleles, at a given locus, produces a less (positive IC) or 
a more severe (negative IC) phenotype than their homoallelic counterparts (96). Thus, IC is 
of particular importance in PKU, since ~75% of the patients are heteroallelic for PAH 
mutations, being classified as compound heterozygous, which means that they have a 
different mutation for each allele (94). Experimental evidences support that genotype does 
predict biochemical phenotype (i.e. by Phe loading tests) but does not predict clinical 
phenotype (i.e. occurrence of intellectual disability) (97). 
2.2.2. PAH PROTEIN 
The PAH protein belongs to a small group of enzymes, known as aromatic amino acid 
hydroxylases (AAAHs) which also include tyrosine hydroxylase (EC 1.14.16.2) and tryptophan 
hydroxylase (EC 1.14.16.4). These enzymes catalyse the hydroxylation of aromatic rings of 
the amino acids L-Phe, L-Tyr and L-Trp in the presence of the cofactor BH4 (98). In addition, 
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for the catalytic reaction, AAAHs require molecular dioxygen (O2) as well as a non-heme iron 
in the ferrous state (Fe(II)) at the active site (98). 
Human PAH is a cytoplasmic enzyme present mainly in the liver, but also expressed in some 
extent in the kidney and epidermis (99,100). Due to its role in the degradation of L-Phe from 
diet, is considered a catabolic enzyme but it also provides an endogenous source of L-Tyr to 
the organism, converting an essential amino acid (L-Phe) into a non-essential one (L-Tyr) 
(101). 
In terms of structure, hPAH is a homotetrameric enzyme that in vitro is found in equilibrium 
with a dimeric form. However, the tetrameric form has been considered the biological active 
form. Each monomer presents 452 amino acids, a molecular mass of ~52 kDa (102), adopts 
an a/b structure and presents three functional and structural domains: (i) an N-terminal 
regulatory domain (residues 1-142), containing the serine residue which is thought to be 
involved in activation by phosphorylation (Ser16 in hPAH); (ii) the catalytic domain (residues 
143-410), containing the non-heme iron atom; and (iii) C-terminal domain (residues 411-452), 
which consist in a dimerization and tetramerization motif  (Figure I.5). The C-terminal domain 
assembles to form the functional dimeric and tetrameric forms of the enzyme (94). 
 
	
FIGURE I.5. Structure of human phenylalanine hydroxylase full-length composite model. (A) 
Structure of a monomer where the iron atom is shown in red; the N-terminus starting over the 
active site, as well as the rest of the regulatory domain is highlighted in blue; the catalytic 
domain in shown in yellow and the tetramerization domain is depicted in green; (B) Structure 
of the native tetrameric form of the enzyme. Adapted from Erlandsen and Stevens (1999) (92). 
The regulation of hPAH activity is known to occur at several levels and includes allosteric 
activation by the substrate L-Phe, inhibition by the cofactor BH4 and an additional activation 
by phosphorylation of Ser16 (103). The tetrameric form of the enzyme displays substrate 
activation and positive cooperativity for L-Phe binding, involving all three functional domains 
and all subunits (104). BH4 acts as a negative regulator by blocking L-Phe activation when the 
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binding to PAH is without L-Phe forming an inactive PAH-BH4 complex. However, recent 
studies demonstrate that when PAH is Phe-ativated, the BH4 binding results in positive 
cooperativity (105). Phosphorylation acts as a mediator of L-Phe activation by decreasing the 
L-Phe concentration required to activate hPAH (104). 
Some of these regulatory properties are mediated by the regulatory domain. In addition, recent 
studies propose that L-Phe not only binds the catalytic domain but also an allosteric site 
localized in the hPAH regulatory domain (106,107). In fact, the hPAH regulatory domain has 
the ACT (Aspartate kinase, Chorismate mutase and TyrA) domain, a structural motif, common 
in several allosteric proteins, which is involved in the binding of small activator molecules, 
usually amino acids and pyrimidines. Recent studies supported an allosteric regulation of 
hPAH, involving the stabilization of this ACT domain upon binding of L-Phe, during hPAH 
activation (103). This could be an important discover to open new ways of protein activation 
by small molecules. 
2.2.3. PKU AS CONFORMATIONAL DISEASE 
The term conformational disease arises to describe disorders that are caused by the 
expression and/or accumulation of unfolded or misfolded proteins and to date it comprises 
more than 40 different conditions (108). The cell biological mechanism by which abnormal 
protein structures lead to conformational diseases is still unclear. However it is known that 
improper protein folding (misfolding) as well as accrual of unfolded proteins can lead to the 
formation of disorder (amorphous) or ordered (amyloid fibril) aggregates (109). 
Apparently, diverse disorders can be classified as conformational diseases as their aetiology 
involves abnormal unfolding followed by aggregation of an underlying protein. Taking into 
account the pathology, proteins can be classified as: (i) naturally unfolded, proteins prone to 
self-aggregation due to their specific amino acid sequence; (ii) proteins that become 
aggregation prone only after post-translational modifications; and (3) proteins that require 
specific mutations to become aggregation prone (108). 
A common feature of conformational diseases with gain-of-functon is that the aggregates are 
usually devoid of helical regions, present in the form of b-sheets and contain high percentage 
of post-translational modifications (109).  
It is presently assumed that more than one half of all sequence alterations in genetic diseases, 
like PKU, are missense mutations, meaning that single amino acid substitutions can affect the 
structure, stability and folding of a protein turning it into a misfolded protein.  
Expression and characterization of several PAH missense mutations in in vitro systems have 
identified at least three main groups of enzymatic phenotypes, which differ in their kinetic 
behaviour and/or stability. The first group include structurally stable mutations with altered 
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kinetic properties; the second group include mutations with normal or almost normal kinetic 
properties, but reduced stability both in vitro and in vivo; and the third group include mutations 
affecting both kinetic and stability properties of the enzyme(96). These mutations are located 
in different regions of the three-domain structures, described earlier. As, the main molecular 
pathogenic mechanism of PAH deficiency is protein misfolding causing protein instability and 
low intracellular levels, due to specific mutations, PKU is now considered a Conformational 
disease with loss-of-function (96,110). 
For protein misfolding diseases therapeutic strategies under investigation, aim to rescue the 
native protein conformation or to induce stabilization of intermediate or misfolded protein 
states. The use of pharmacological chaperones (PC) and proteostasis regulators (PR) to 
rescue folding defects in proteins involved in conformational diseases have been recently 
explored (33,42). Actually, PC are small molecular weight compounds that usually resemble 
natural ligands of the target proteins and they act by stimulating protein renaturation or 
scaffolding the final folded structure. For example, in the case of PKU, the cofactor BH4 is a 
natural ligand acting as a PC, especially when given as therapeutic supplementation (111). 
There are groups that have been working on the identification of PCs in order to treat PKU 
(111,112). One of the groups performed a high-throughput ligand screening and, from the over 
1000 pharmacological agents testes, they identified 4 compounds that improved hPAH 
thermal stability and did not show relevant inhibition of hPAH activity (111). The other group, 
developed PCs by virtual screening using BH4 as query structure and identified 84 candidates 
with potential to bind the active site of hPAH (112). 
Although these studies demonstrate interesting perspectives in terms of increasing hPAH 
activity, recently, Patel et al. disclosed the possibility to develop a new generation of PCs that 
specifically target the regulatory domain. This emerging model of PAH allosteric regulation, 
proposes that L-Phe not only bind the hPAH catalytic domain but also a site at the hPAH N-
terminal regulatory domain, to activate the enzyme via an unclear mechanism (113). The 
synthesis of L-Phe like molecules that could act in such manner would be a stabilization 
strategy to target the allosteric domain and may constitute an alternative approach for the 
treatment of hPAH missense mutation that are non-responsive to BH4 supplementation and 
that belong to the group of mutants with normal or almost normal kinetic properties, but 
reduced stability both in vitro and in vivo. 
2.2.4. THE p.G46S MUTANT AS A MODEL TO STUDY SEVERE FORMS 
OF PKU 
As mentioned, the majority of variant hPAH, when over-expressed in prokaryotic systems, 
have a propensity to self-associate and form soluble/insoluble aggregates but when produced 
in eukaryotic cells are rapidly degraded (114). There are no evidences about the exactly 
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cellular mechanism that leads to protein degradation or which are the cellular protein quality 
control pathways and the molecular chaperones involved in this homeostatic response in this 
type of variants.  
The substitution of a glycine by a serine in residue 46 of the hPAH, leads to the p.G46S variant 
(hPAH-G46S). This protein belongs to the group of enzymatic phenotypes with reduced 
stability, both in vivo and in vitro, which results in a severe form of PKU (115). The p.G46S 
variant results from a G to A transition in cDNA position 136 (c.136g>a) of exon 2 and was 
first identified by fluorescence-based single-strand conformation polymorphism (F- SSCP) 
analysis on PKU haplotype 5.9 alleles (115). The G46 residue is located in the regulatory 
domain of hPAH that contains the ACT module. Residue Gly46 is located at the start of α-
helix 1 (Ala47– Glu57), in a five residue (Leu41–Gly46) loop stabilized by a network of 
hydrogen bonds and a salt-bridge (Lys42– Glu44). It has been proposed that the G46S 
substitution will lead to the extension of α-helix 1 that then perturbs the α-β sandwich of the 
ACT module in the regulatory-domain (Figure I.6) (114). The prokaryotic expression of the 
hPAH G46S variant as a fusion protein coupled to the maltose binding protein (MBP) via a 
peptide sequence recognized by the factor Xa restriction protease (MBP-pep(FXa)-PAH-
G46S), gave rise to a metastable tetrameric form characterized by a near normal catalytic 
efficiency (114). However, destabilization and self-association of the G46S tetramer (and 
dimer) and the formation of higher-order oligomers and large twisted non-amyloid fibrils were 
evident (Figure I.6), after the cleavage of the MBP fusion partner by the restriction protease 
factor Xa (114). 
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FIGURE I.6. Representation of the human phenylalanine hydroxylase monomer with the 
localization of residue Gly46 (A) and the self-association of the G46S tetramers (B).  In panel 
(A) the interactions established by the Gly46 residue are shown; the regulatory domain is 
shown in green while the catalytic and tetramerization domains are depicted in red.  Panel (B) 
shows the time-course of the self-association of MBP-pep(FXa)-hPAH-G46S () and MBP-
pep(FXa)-PAH-WT (p) following the cleavage by factor Xa; the graphic inset represents SDS-
PAGE analysis of the cleavage reaction at time 0 (lane 2), 10 (lane 3), 20 (lane 4) and 30 
minutes (lane 5); the electron micrographs of negatively stained hPAH-G46S at the maximum 
of light scattering (120 min; arrow) are also shown. Adapted from Leandro et al (114). 
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The variant p.G46S has been well characterized by Leandro and collaborators (114) in terms 
of the intrinsic physico-chemical properties, as well as extrinsic factors such as ionic strength, 
temperature, pH, protein concentration, phosphorylation state and deamination and it is 
considered a well-controlled model to study not only PR involved in protein degradation but 
also new PC that specifically target the regulatory domain as a stabilization strategy, with aim 
of to prevent self-association and to restore hPAH activity (79,96,114). 
2.3. PKU TREATMENT 
Currently, as there is no cure for PKU, the main goal in PKU treatment is to lowering L-Phe 
levels to prevent intellectual disability but maintaining the minimum levels required for normal 
growth. Therefore, the prevailing treatment is dietary restriction of L-Phe, supplemented with 
specifically designed medical foods (116).  
The establishment of newborn screening programmes along with prompt institution of dietary 
treatment has prevented intellectual disability, although neurophysiological and 
neuropsychological impairments may still persist in treated patients (117–121). This dietetic 
restriction has, as major advantage, the applicability towards all hPAH mutations with an 
adequate outcome, but, as disadvantage, this strict long term diet can lead to social boundary, 
nutritional deficiencies (in vitamin B12, vitamin D, calcium, iron and unsaturated long chain 
fatty acids), which may exacerbate the neurological problems, as well as non-compliance due 
to poor palatability, despite the recent improvement of low-Phe dietetic products (122,123).  
Therefore, there is an urgent need for exploring new approaches and alternatives to partially 
or totally substitute the L-Phe diet.  
2.3.1. CURRENT TREATMENTS 
Besides, dietary restriction of L-Phe intake, which remains the mainstay of treatment for PKU 
since its introduction in 1953 (124), the cofactor BH4, LNAA and glycomacropeptide (GMP) 
supplementation, are the current available approaches for PKU treatment (116). 
The responsiveness to BH4 therapy is likely to be associated with mutations in the PAH gene 
resulting in some residual enzyme activity, characteristic from patients presenting the mild 
PKU phenotype, however genotype-phenotype correlations are inconsistent (125). 
Sapropterin dihydrochloride (KuvanÒ, Biomarin Pharma) is a synthetic formulation of the active 
6R-isomer of the naturally occurring hPAH cofactor, orally administered to patients for PKU 
treatment. The mechanism of action in lowering L-Phe levels, in patients with PKU, has not 
been fully elucidated, but appears to be related, in part, to its effect in stabilizing mutant hPAH 
enzymes, resulting in increased clearance of L-Phe from the body. In patients with BH4 
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deficiency, its mechanism of action is presumed to be secondary to replacement of 
endogenous tetrahydrobiopterin (126). 
Kuvan has received Orphan Drug status for the treatment of PKU, since phase II and III clinical 
data demonstrated that it was a safe and effective therapy (127). In fact, this therapeutic 
approach has proven successful in significantly increasing L-Phe tolerance allowing patients 
to relax their diet and in some cases discontinuing the L-Phe restrictive diet (128,129). 
However, for 90% of patients with classical PKU, who comprise about 50-80% of patients 
detected by newborn screening, this therapy has no beneficial effect (130). So, alternative 
treatments for which efficacy is not dependent on genetic variations in the PAH gene may 
benefit these patients. 
The LNAAs had been shown to reduce CNS L-Phe concentrations and consequently, cerebral 
damage, despite the observed increased plasma levels. This might be due to the fact that the 
administered LNAAs will compete with L-Phe to cross the BBB (89). Although LNAA treatment 
appears to have beneficial effect on executive functioning, this approach is only suitable for 
adults who are not adhering to a low Phe diet (131). In addition, regarding long term outcome, 
clinical data using this treatment strategy are not yet available (131), requiring additional 
studies to prove its safety and efficacy (132). 
Glycomacropeptide (GMP) is a protein derived from cheese whey, naturally low in L-Phe, rich 
in valine, isoleucine and threonine, that when supplemented with the essential amino acids 
(L-Tyr, L-Trp, arginine, cysteine and histidine) can be a useful adjunct to the L-Phe restricted 
diet also improving palatability (133). It has been shown that the potential benefits of having 
GMP included in PKU diet are reduced ureagenesis, improved protein retention and L-Phe 
utilization (134), decreased levels of postprandial ghrelin concentration when compared to an 
amino acid diet (135) and increased metabolic activity (in PKU mice) (136). From this last 
study, the authors conclude that the GMP diet provides a more natural and physiological low 
L-Phe source of intact protein as compared with the synthetic amino acid (136). Although, the 
present data are promising, further studies are needed to investigate the effect of the GMP 
diet in humans, once the majority of the studies were performed in mice. This will allow further 
evaluation of the safety and efficacy of GMP consumption for long term. 
2.3.2. FUTURE TREATMENT STRATEGIES 
All the previous mentioned data highlight the need for alternative strategies for PKU treatment. 
Enzyme replacement therapy with PAH-based fusion proteins and protein delivery systems, 
along with genetic therapy and pharmacological chaperones are some of the therapeutic 
strategies that have been studied in order to answer this demand. 
Enzyme substitution therapy using phenylalanine ammonia lyase (PAL; E.C.4.3.1.5) has been 
suggested as a possible therapeutic approach for PKU. PAL is an enzyme that catalyses the 
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conversion of L-Phe into transcinnamic acid and insignificant amounts of ammonia, and unlike 
PAH, is a monomer and requires no cofactors (137). Initially, when PAL started to be 
administered in enteric-coated gelatine capsules to PKU patients, showed reduction in L-Phe 
levels but, following repeated model injections, an immune response was elicited resulting in 
a significant decrease in half-life (138). In addition, when administered orally, low activity of 
PAL in gastric secretions was found due to protease degradation (138). Later, to overcome 
these issues, more efficient forms of PAL have been made by site-directed mutagenesis and 
chemical modification with polyethylene glycol (PEG). The outcome was the maintenance of 
PAL specific activity, reduced immunogenicity with prolonged half-life in the PKU mouse 
model (139–143). This PAL formulation has started phase II clinical trials (143) and, despite 
the progression into phase III clinical trials, pre-clinical studies indicate that weekly injections 
are required to sustain a significant decrease in L-Phe levels in the PKU mice for up to one 
year (142). Moreover, PEG-PAL dosing regimen was gender-dependent (142). 
In summary, although the positive results this therapy achieved, the route of administration 
would be invasive and painful to the patients and a burden to their families. It would be inherent 
to repeated injections, physiological stress pain, cost and risks of infection. Oral administration 
would be a much more convenient way of delivery, however, in general, oral delivery of 
enzymes have been resulting in insufficient bioavailability (138).  
Approaches which use probiotics and genetically modified (GM) probiotics have gained wide 
attention. Probiotics are live microorganisms that confer health benefits on the host, when 
administered in adequate amounts (144). There are extensive reports in the literature 
regarding the beneficial effects of probiotics in certain conditions, such as inflammatory bowel 
disease (145,146). Moreover, advances in genetic engineering of probiotics have made 
possible to increase their beneficial effect potentially targeting a wider range of disorders. 
Regarding PKU, the PAL enzyme has been expressed in GM organisms and orally deliver to 
animal models of the disease (138,147–149). The obtained data showed a reduction of 31% 
in plasma L-Phe levels after one hour, a further 44% reduction after two hours and also. 
Furthermore, PAL contained within E. coli was resistant to proteolytic inactivation by intestinal 
enzymes in vitro (138). However, there are safety concerns regarding the use of E. coli for 
delivering enzymes to the gastrointestinal tract as there is a potential risk that engineered E. 
coli interacts with its wild type form present in the normal gut flora (150). So, studies were 
performed expressing PAL in L. lactis resulting in a  significant reduction in L-Phe levels in 
treated rats. However, the animals used did not represent an orthologous model to human 
PKU (147). These data suggest that GM probiotics may be useful as alternative therapy for 
PKU and may allow PKU patients to relax their diet. However, as any of the other approaches, 
more studies are needed to evaluate the safety and efficacy of these GM modified probiotics 
in a short and long-term setting. 
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Regarding gene therapy, the goal is to deliver a functional PAH gene into the liver cells, as 
the activity of PAH is primarily in the liver. To accomplish that, several types of viral vectors 
have been examined for their potential to correct PKU either using mouse models or  
hepatocytes derived from these mouse models. Assays using an adenoviral vector containing 
the hPAH-cDNA infused into the liver through portal vein of PKU mice (151) showed a 
therapeutic effect, that however ceased after a few weeks. Recombinant adeno-associated 
virus (rAAV) vectors have gained increasing attention as they do not carry any viral genes and 
therefore elicit minimal immune responses. However the reduction in L-Phe levels was only 
noted in male PKU mice (152). Recently, the transfer of foreign genes using non-viral vectors 
into tissues or organs by direct injection of naked plasmid-DNA started to be achieved, leading 
to transgene expression and therapeutic response. This approach allows no size limitation of 
the DNA insert and no potential cytopathic side-effect, but the gene transfer rate and the 
transient transgene expression are lower (153). The use of Minicircle (MC) naked-DNA 
vectors is another recent explored strategy and already demonstrated that it is possible to 
express the murine PAH cDNA leading to normalisation of blood L-Phe levels in a PKU mouse 
model (154). This data showed that the use of MC-DNA may offer improved safety and efficacy 
as a potential genetic treatment for PKU and also liver diseases (154).  
Although the described studies provide a step forward to achieve efficiency and stability of 
cDNA delivery, more research is required to create more robust and stable vectors before 
implementing gene therapy. 
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About 1 in 800 live births are affected by inherited metabolic disorders (IMD). IMDs represent 
a vast, diverse and heterogeneous collection of around 700 genetic rare diseases that are a 
significant cause of morbility and mortality, especially in childhood. By 2015 only ≈5% of rare 
diseases had available pharmacological treatments, which highlight the need for the 
development of therapeutic options for this group of patients. 
Phenylketonuria is one of the most known IMD, with more than 900 mutations described to 
date. When untreated, causes a wide phenotypic spectrum ranging from mild to severe 
psychomotor impairment due to neurotoxic accumulation of L-Phe and the low levels of L-Tyr 
which, in turn, affect the biosynthesis of several neurotransmitters such as catecholamines. 
The current treatment available consists in a life-long L-Phe-free diet initiated in the first days 
of life, as soon as possible after diagnosis by newborn screening programmes. The 
administration of KUVAN® (sapropterin dihydrochloride), a synthetic formulation of BH4, the 
naturally occurring hPAH cofactor, is also an available treatment introduced very recently, due 
to its pharmacological chaperone-like activity. However, lack of diet compliance resulting in 
poor metabolic control and the non-responsiveness of KUVAN® treatment by patients with 
severe forms of PKU, emphasise the urgent need for new therapeutic approaches. 
Recently, Leandro et al. and other groups has shown that PKU is a misfolding disease with 
loss of function, since the majority of the mutations result in proteins displaying disturbed 
oligomerization, decreased stability and accelerated degradation. A novel therapeutic strategy 
to ameliorate misfolding diseases relies in the adaptation of the cellular proteostasis. 
Therefore, small molecules acting as pharmacological chaperones and/or proteostasis 
regulators could be used to modulate the balance between folding and degradation, which in 
loss-of-function conformational diseases is compromised. In addition, despite limited 
application of proteins as therapeutic agents due to their complex nature and instable 
structure, one of the most promising therapeutic strategy to PKU is enzyme replacement 
therapy.  
In the latest years, the Metabolism and Genetics (Met&Gen), Bioorganic Chemistry and 
Nanostructured Systems for Overcoming Biological Barriers (Nano2B) groups from the 
Research Institute for Medicines (iMed.ULisboa) have been devoted to the development of 
new strategies for PKU treatment either through the synthesis of small molecules acting as 
pharmacologigal chaperones and/or enzyme activators or through and enzymatic 
replacement therapy approach. Previous work of the Met&Gen group suggests that the severe 
p.G46S hPAH variant (associated with a severe PKU phenotype) is a useful model to be used 
in the systematic in vitro studies to assess the ability of small molecules to inhibit hPAH 
aggregation. In addition, the group have also been working, together with Nano2B group, in 
the development of an enzymatic replacement approach, where a nano-system based on 
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chitosan (CS) to encapsulate hPAHwt has been studied not only to protect the enzyme during 
formulation but also to be used as a delivery system.  
 
The present thesis intends to continue the collaborative work that has been developed within 
the Met&Gen, Bioorganic Chemistry and Nano2B groups. Therefore, this project aims to: 
(i) Study the effect of several small compounds synthesized by the Bioorganic Chemistry 
group upon the aggregation of the hPAH-G46S variant, in vitro and in cellulo, hoping to 
contribute to the identification of a new class of pharmacological chaperones;  
(ii) Identify and validate therapeutic targets within the components of the cytosolic proteostasis 
network in order to develop new pharmacological options for the treatment of severe forms of 
PKU (such as the p.G46S variant) by using small molecules that could function as proteostasis 
regulators;  
(iii) Evaluate the stability and activity of nanoencapsulated hPAHwt in a cellular environment, 
in order to validate the previously optimized delivery system. 
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1. MATERIALS 
1.1. REAGENTS 
The Isopropyl β-D-1-thiogalactopyranoside (IPTG) and lysozyme were obtained from Nzytech. 
Ferrous ammonium sulfate was from Merck. The protease inhibitor phenyl-methylsulfonyl 
fluoride (PMSF), the cofactor BH4, L-Phe, Hepes, dithiothreitol (DTT), low molecular weight 
CS (50-190 kDa) with a deacetylation degree of 91.8 % and tripolyphosphate (TPP) were 
purchased to Sigma-Aldrich. The amylose resin and the restriction protease factor Xa were 
obtained from New England Biolabs. 
The ISOLATE II Mini Kit from Bioline was used for DNA purification. Branched 
polyethylenimine (PEI) 25 kDa from Sigma-Aldrich and LipofectamineÒ LTX reagent from 
Invitrogen were used as co-transfection agents. Opti-MEM® I reduced-serum medium was 
obtained from Thermo Fisher.  
For the cell culture assays, RPMI medium, bovine serum, penicillin and streptomycin were 
obtained from Invitrogen. The Magnetic Beads, used in the co-immunoprecipitation assays, 
was delivered by Bio-Rad. 
1.2. EXPRESSION VECTORS 
1.2.1. pTrcHis  
The prokaryotic expression vector pTrcHis (appendix 1) was used to produce the wild-type 
PAH enzyme and was obtained from Invitrogen. The hPAH cDNA (GenBank U49897) had 
already been cloned into the BamHI site of pTrcHis vector and the expression system has 
been previously validated by the research group (155). The expression construct contains a 
sequence that encodes a hexahistidyl peptide (6xHis tag), N-terminally to the recombinant 
hPAH that function as a metal binding domain in the translated protein allowing purification of 
the recombinant protein by immobilized metal affinity chromatography (IMAC). It also contains 
a codifying sequence for an amino acid sequence presenting the cleavage recognition site for 
the protease enterokinase (EK) between the metal binding domain and the recombinant 
protein which allows the subsequent removal of the N-terminal fusion peptide from the purified 
recombinant protein. 
1.2.2. pMAL-c2X 
The prokaryotic expression vector pMAL-c2X (Appendix 2) was from New England Biolabs 
and was used to produce the recombinant hPAH-G46S. The hPAH cDNA has been already 
cloned  according to the procedures described in (96). The hPAH-G46S cDNA was inserted 
downstream from the nucleotide sequence encoding the maltose binding protein (MBP) N-
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terminally to the hPAH-G46S, resulting in the expression of an MBP fusion protein which can 
be purified by affinity chromatography using an amylose resin. The pMAL-c2X vector also 
contain a sequence encoding for an amino acid sequence recognized by the protease Factor 
Xa (FXa), located just 5’ to the polylinker insertion sites, which allows MBP to be cleaved from 
the protein of interest after purification. 
1.2.3. pEXP51  
The pEXP51 vectors were used to build the molecular chaperones library.  These vectors 
were obtained through the Gateway™ cloning technology from Invitrogen. This approach 
utilizes the pEF-DEST51, a destination vector for cloning and expression of C-terminal fusion 
proteins in mammalian cells. The Gateway technology consists in cloning the target gene in 
the pENTR vector in FUSION format (containing flanking attL sites, the Kozak sequence at 
the 5’ terminus and no stop codon at the 3’ terminus), and further recombine them with 
destination vectors (pDEST) that contain attR sites and the backbone of the final expression 
vector. The recombination between pENTR vector and pDEST vector result in the pEXP51 
expression vector (Figure VIII.4) (156,157). Using these vectors the molecular chaperones 
are expressed in fusion with a N-terminal 6xHis tag. 
1.3. BACTERIAL STRAINS AND EUKARYOTIC CELL LINES 
The hPAH-G46S protein was expressed in Escherichia coli TB1 (F- ara Δ(lac-proAB) 
[Φ80dlac Δ(lacZ)M15] rpsL(StrR) thi hsdR) obtained from New England Biolabs (USA), while 
the hPAHwt protein was expressed in Escherichia coli TOP10 (F-, mcrA Δ (mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL endA1 nupG) 
from Invitrogen. 
For the mammalian cell culture studies, three different cell lines were used namely the HEK-
293T cells (human embryonic kidney epithelial cell line, ATCC CRL-11268), the HepG2 cells 
(human hepatocellular carcinoma cell line, ATCC HB-8065) and the COS-7 cells (CV-1 cell 
line with an Origin defective mutant of SV-40, ATCC CCL-70). 
1.4. MOLECULAR CHAPERONES 
The molecular chaperones studied in this work are presented in Table III.1 and were cloned 
in the appropriate eukaryotic expression vector according the Gateway technology (Invitrogen) 
during Met&Gen group’s previous work as described in 1.3. 
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TABLE III.1. Molecular Chaperones screened for their interaction with the hPAH-G46S variant 
form. 
Molecular 
Chaperone 
MM 
(kDa) 
Expression 
vector 
Main role Reference 
HSP90AB1 
Heat shock protein 
HSP 90-beta 
UniProtKB–P08238 
90 
 
pEXP51V5/His85 
Promotes maturation, structural 
maintenance and proper regulation 
of specific target proteins. Interacts 
dynamically with various co-
chaperones that modulate its 
substrate recognition, ATPase 
cycle and chaperone function 
(158) 
HSPA8 
Heat shock cognate 
UniProtKB-P11142 
71 pEXP51V5/His553 
Participates in ER-associated 
degradation (ERAD) quality control 
pathway. 
(159) 
HSPA2 
Heat shock-related 
protein 2 
UniProtKB-P54652 
70 pEXP51V5/His555 
Plays a pivotal role in protein 
quality control system, ensuring 
the correct folding of proteins, the 
re-folding of misfolded proteins 
and controlling the targeting of 
proteins for subsequent 
degradation. 
(160) 
HSPH1 
Heat Shock Protein 
UniProtKB–Q92598 
105 pEXP51V5/His556 
Member of the Hsp70 super family, 
independently prevents the 
aggregation of misfolded proteins. 
(161) 
SQSTM1 
Sequestosome-1 
UniProtKB-Q13501 
50 pEXP51V5/His575 
Required both for the formation 
and autophagic degradation of 
polyubiquitin-containing bodies. 
(100) 
 
1.5. TESTED COMPOUNDS 
A library of 17 different derivatives of 3-hydroxyquinolin-2(1H)-one (3HQ) was utilized to follow 
the inhibition of hPAH-G46S aggregation after FXa cleavage. These compounds were 
synthesized by the Bioorganic group (iMed.ULisboa) and are presented in table III.2. 
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TABLE III.2. Library of quinoline derivative compounds tested for inhibition of hPAH-G46S 
aggregation 
Compound Structure Compound Designation Molecular Mass 
 
C2 464.39 
 
C4 364.06 
 
 C6 360.24 
 
C8 349.26 
 
C9 345.27 
 
C10 393.31 
 
C11 421.36 
 
C12 384.42 
 
C14 392.32 
 
C15 392.32 
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C16 436.33 
 
C17 446.33 
 
C18 416.34 
 
C19 554.52 
 
C20 398,39 
 
C21 380.40 
 
C22 414.84 
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2. METHODS 
2.1. EXPRESSION AND PURIFICATION OF hPAH-G46S 
For the expression of recombinant hPAH-G46S, 100 μL of E. coli TB1 competent cells were 
transformed with 10 ng (5 μL) of the DNA construct (pMAL-MBP-Xa-hPAH-G46S). The cells 
were grown overnight (ON) at 37°C, on solid LB (tryptone 1%, yeast extract 0.5%, NaCl 0.17 
M, pH 7, agar-agar 1.5%) containing ampicillin (LB/Amp) at 100 μg/mL. An isolated colony 
was selected to inoculate 10 mL of LB/Amp medium. After ON incubation, at 37°C with 
constant stirring (≈110 rpm; Selecta Rotabit 3000974 orbital shaker), the bacterial suspension 
was diluted in 1L (1:100) of LB medium with 50 μg/mL Amp, 200 μM ferrous ammonium 
sulphate and 0.2% of glucose and was incubated at 37°C with constant stirring (≈160 rpm; 
Selecta Rotabit 3000974 orbital shaker) until reach an optical density of ≈0.6 at l600 nm 
(OD600nm). At this time point, the medium was supplemented  with 1 mM isopropyl-thio-β-D-
galactoside (IPTG) (to initiate hPAH-G46S expression) and 200 μM ferrous ammonium 
sulphate. After incubation during 3 h, at 28°C, at 160 rpm, a novel supplementation of 200 μM 
ferrous ammonium sulphate was performed and the medium was maintained at 28ºC for an 
extra 2h with constant stirring (160 rpm). The bacterial cell pellet was then obtained by 
centrifugation at 3220xg, during 15 minutes at 4°C and washed with cleaning buffer (20 mM 
KH2PO4, 0.15M NaCl, 1mM EDTA, 1mM PMSF, pH 7.5). The bacterial pellet was stored at -
20°C for a short period (no more than three months), until being used. 
In order to prepare the sample for purification, the pellet was ressuspended in MBP-lysis buffer 
(10 mM NaHepes, 200 mM NaCl, pH 7.4, 1 mM EDTA, 1 mM PMSF, pH 7.25) containing 
lysozyme (1 mg/mL) and DNAse (≈5 μg) in a ratio of 1 L of culture/10 mL of MBP-lysis buffer. 
After 30 minutes of incubation, at 4°C, cells were lysed by sonication (Sonics Materials - 
VibraCell), through 3 cycles of 60 seconds each (with a duty free cycle of 50%). Between each 
cycle, the lysate was maintained during 30 seconds, at 4ºC, to allow the sample cooling down. 
The suspension was then centrifuged at 12800xg centrifugation during 40 min, at 4°C, to 
separate the cellular residues and aggregated proteins from the soluble cytoplasmic fraction 
which was used to isolate the recombinant hPAH-G46S protein. 
The variant protein was then purified by affinity chromatography using 60 mL of amylose resin 
(New England Biolabs), at 4ºC. The column was previously equilibrated with 4 volumes of 15 
mM NaHepes, 200 mM NaCl, 1 mM EDTA, pH 7.4. After injection of the cell lysate, the column 
was washed with 12 volumes of MBP-washing buffer (15mM NaHepes, 200 mM NaCl, pH 
7.4). The recombinant hPAH-G46S was eluted using MBP-elution buffer (MBP-washing buffer 
containing 10 mM maltose). The solvents were pumped at 0.8 mL/min. 
The tetrameric form of the variant recombinant protein was further isolated by size exclusion 
chromatography (SEC) using a prepacked HiLoad 16/60 Superdex 200 column (1.6 cm x 60 
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cm) from GE Healthcare, at 4°C. The mobile phase consisted of 20 mM Na-Hepes, 200 mM 
NaCl, pH 7.0 (SEC buffer) and the flow rate was 0.7 mL/min. The relative molecular mass 
(MM) of the different oligomeric forms was estimated from a calibration curve obtained using 
standard proteins (from Sigma), at a concentration of 5 mg/mL each: cytochrome C (12.4 
kDa), ribonuclease A (13.7 kDa), myoglobin (17.6 kDa), β-lactoglobulin (18.4 kDa), ovalbumin 
(45 kDa), BSA (66 and 132 kDa), alcohol dehydrogenase (150 kDa), β-amylase (200 kDa) 
and apoferritin (443 kDa). 
The tetrameric hPAH fusion protein was collected and concentrated by Amicon Ultra 15 
centrifugal filter device (50 kDa MWCO; Millipore) until reaching a concentration of ≈ 9 mg/mL. 
The amylose affinity purification and the SEC were performed on a FPLC (Fast Protein Liquid 
Chromatography) system, namely the AKTA Prime Plus (GE Healthcare), equipped with a UV 
detector (l280 nm) and a fraction collector. 
2.2. EXPRESSION AND PURIFICATION OF hPAHWT 
For the expression of the hPAHwt, 100 μL of E. coli TOP 10 competent cells were transformed 
with 10 ng (5 μL) of the appropriate DNA construct (pTrcHis-hPAHwt) to produce the hexa-
histidyl hPAH fusion protein.  
An isolated colony was used to inoculate 10 mL of LB/Amp medium. After ON incubation, at 
37ºC, with constant stirring at 110 rpm, the medium was used to inoculate 1L of LB/Amp 
medium and cells were grown at 37°C until reach an OD600nm ≈0.6. The expression of the 
recombinant hPAHwt was induced by the addition of 1 mM IPTG. At this time point 0.2 mM 
ferrous ammonium sulphate was also added to the culture medium. After 3h incubation, at 
37°C, with constant stirring (160 rpm) bacterial cells were harvested by centrifugation at 
3220xg, during 15 min, at 4°C. The bacterial pellet was stored at -20°C for a short period (no 
more than three months), until being used. 
For purification, the bacterial pellet was ressuspended in 6xHis lysis buffer (50 mM 
KH2PO4/K2HPO4, pH 7.8, 300 mM NaCl, 10% de glycerol) containing lysozyme (1 mg/mL), 
PMSF (1 mM) and DNAse (≈ 5 μg) in a ratio of 1 L of culture/10 mL of 6xHis lysis buffer. After 
30 min of incubation, at 4°C, cells were lysed by sonication as described previously. The cell 
lysate was centrifuged at 12800xg, during 40 min, at 4°C, to separate the cellular residues 
and aggregated insoluble proteins from the soluble protein fraction.  
The soluble fraction was used to purify the recombinant hPAHwt fusion protein by IMAC in a 
ratio of 10 mL lysate/500 µL resin. Before being used the Ni-NTA resin was washed 3x with 1 
mL of Milli-Q water and 3x with 1 mL of 6xHis-lysis buffer containing 10 mM imidazole. 
Between each step of washing and conditioning, the suspension was centrifuged at 360xg, 
during 2 min, to remove the supernatant. The Ni-NTA resin was then incubated with the 
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soluble fraction (previously supplemented with imidazole and β-mercaptoethanol at a final 
concentration of 10mM each) during 1h, at 4°C, with constant stirring. The suspension was 
then packed into a 9 cm polypropylene conical column (Poly-Prep columns; BioRad), and 
purification was performed, at 4 °C, using the 6xHis-lysis buffer containing increased 
concentrations of imidazole solutions (gradient): (i) washing steps of  2x 5 mL 20 mM imidazole 
, 2x 5 mL 50 mM imidazole and 1x 5 mL 75 mM imidazole; (ii) elution step 4x 500 µL 250 mM 
imidazole.  
In order to isolate the oligomeric forms of hPAHwt, the FPLC system previously described was 
used The tetrameric fusion protein was concentrated using an Amicon Ultra 15 centrifugal 
filter (50 kDa MWCO), until reaching a concentration of ≈ 9 mg/mL. 
2.3. SDS-PAGE PROTEIN ANALYSIS 
When required, either the variant or the hPAHwt protein were analysed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) according to the Laemmli’s method 
[9]. For the resolving gel, a 10% acrylamide/bis-acrylamide solution (30% T and 2.6% C; Bio-
Rad) and the 0.375 mM Tris-HCl, pH 8.8, 0.1% SDS buffer was used. The stacking gel 
contained 4% acrylamide/bis-acrylamide and the 0.125 mM Tris-HCl, pH 6.8, 0.1% SDS 
buffer. The electrophoresis buffer contained 62.5 mM Tris, 192 mM Glycine, 0.1% SDS and 
pH 8.3. The samples were applied to the system after being denatured at 95°C, during 10 min, 
in loading buffer solution (62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 0.025% 
bromophenol blue and 5% β–mercaptoethanol). The electrophoresis was performed on the 
vertical system Mini-PROTEAN® Tetra handcast (Bio-Rad). To induce electrophoretic 
separation, a constant current of 20 mA was applied. After electrophoresis proteins were 
visualized using the BlueSafe (Nzytech) dye. 
The molecular masses of the proteins were estimated by comparison with the electrophoretic 
profile of NzyColour protein marker II (Nzytech), a ready-to-use mixture of 12 highly purified 
pre-stained proteins, covering a wide range of molecular weights from 11 to 245 kDa.  
2.4. PROTEIN QUANTIFICATION (BRADFORD/BCA METHODS) 
The concentration of purified fusion protein was measured by two different colorimetric 
methods namely the Bradford and the Bicinchoninic acid (BCA) assays, and solutions of 
bovine serum albumin (BSA) as the standards. For the Bradford assay (163) the Bio-Rad 
Protein assay reagent (Bio-Rad) was used. The final volume of the reaction was 1 mL and 
absorbance were measured at λ595 nm in a spectrophotometer Shimadzu (UV1800) using as 
standards BSA solutions from 1 to 10 µg/mL. The BCA assay (164) was performed using the 
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BCA reagent (Sigma) and the absorbance were measured at λ562 nm in a microplate reader 
FLUOstar Omega (BMG LABTECH). All the assays were performed in triplicate. 
The BCA assay was used to quantify indirectly the percentage of protein encapsulation, 
through determination of the protein concentration in the supernatant after nanoparticle 
deposition, as any of the formulation compounds is not a method interferer. 
2.5. FXa INHIBITION ASSAY  
The FXa inhibition assay was performed in order to rule out compounds that have the ability 
to inhibit/inactivate the FXa protease. Changes in the cleavage rate of a synthetic substrate 
of FXa in the presence of the compounds was measured in real-time through 60 
measurements during 30 min by fluorescence spectroscopy using the FLUOstar Omega 
microplate reader. The assay was performed in a 96 well plate. The final volume of the reaction 
was 200 µL and contained the reaction buffer (20 mM Na-Hepes, 100 mM NaCl, pH 7.0), 5 
µg/mL of Factor Xa, 50 µM of the substrate Z–Gly–Gly–Arg–AMC (I-1140; Bachem), and in 
the presence of 100 µM of 3-HQs derivatives (1% DMSO). Reaction was performed at 30°C, 
using λexc360 nm and λem460 nm. Appropriate controls were performed using substrate alone 
with 1% DMSO (Negative Control) and enzyme with no compounds and 1% DMSO (Positive 
Control). 
2.6. hPAH-G46S AGGREGATION ASSAY 
In order to study the influence of the 3HQs derivatives on the self-association process of hPAH 
G46S, cleavage of the purified MBP-hPAH-G46S protein by FXa in the presence and absence 
of the compounds was performed. The fusion protein (0.74 mg/mL) was incubated, at  30°C, 
in a reaction mixture containing 20 mM Na-Hepes, 100 mM NaCl, pH 7.0, factor Xa (at a final 
ratio (by weight) of 1:150 relative to the fusion protein) and 100 µM (1% DMSO) of tested 
compounds. Before the assay, the protein was centrifuged, at 2000 xg, for 15 min, at 4°C. The 
aggregation profile was followed in real-time by light scattering, measured by the increase in 
apparent absorbance at λ350 nm on a FLUOstar Omega microplate reader. The reaction was 
followed during 180 min with shaking before each measurement. The data was fitted to a 
plateau followed by one phase association equation: 
 𝑦 = 𝑦# + 𝑃𝑙𝑎𝑡𝑒𝑎𝑢 − 𝑦#	 ×(1 − 𝑒01 2023 )             Equation II.1 
 
where x0 is the time at which the increase in absorbance begins (lag phase), y0 is the average 
absorbance at time x0, plateau is the y value at infinite time and k is the rate constant.  
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2.7. NANOPARTICLES PREPARATION 
The particulate system was obtained by ionic gelation using a slight modification of a 
previously described method (165,166). Chitosan (CS) stock solution was prepared at 10 
mg/mL in 1% (v/v) acetic acid and tripolyphosphate (TPP) stock solution at 10 mg/mL in MilliQ 
water. Stock solutions were individually diluted to the desired concentrations in SEC buffer 
and blank nanoparticles (NP) were instantly formed when TPP was added to CS at a fixed 1:5 
(TPP:CS) volume ratio.  
For the preparation of protein loaded CS NP, isolated hPAHwt tetramers in a solution of 250 
µg/mL were incubated with TPP solution at concentrations suitable to maintain the volume 
ratios of the blank nanoparticle formulations. The hPAHwt concentration had been optimized 
through previous work (167). The pH of the CS solution with concentration of 1 mg/mL was 
also studied and indicated that must be adjusted to 5.5. The nanoparticles were instantly 
formed when TPP + protein solution was added to CS.  
2.8. NANOPARTICLES CHARACTERIZATION 
2.8.1. PARTICLE SIZE AND ZETA POTENTIAL 
The mean particle size and polydispersity index (PI) were determined by photon correlation 
spectroscopy on a Zetasizer Nano-S (Malvern Instruments) and zeta potential was measured 
through laser Doppler anemometry on a Zetasizer Nano-Z (Malvern Instruments). Samples 
were diluted in filtered MilliQ water (0.45 µm filter; Millipore). In all cases, mean values were 
obtained from the analysis of three different batches, each of them measured three times. 
Results were expressed as mean ± standard deviation (SD).  
2.8.2. ENCAPSULATION EFFICIENCY 
Nanoparticle production yield was determined using an indirect method based on the 
quantification of the protein present in the supernatant after nanoparticle deposition by 
centrifugation at 40000xg, for 30 min, at 4ºC. The amount of protein present in the supernatant 
was determined using the BCA assay. All the samples were analysed in triplicate. The 
encapsulation efficiency (EE) was determined using the equation : 
 EE	 % = [89:;]=>=?@0	[89:;]A>B[89:;]=>=?@ ×100             Equation II.2 
 
where [hPAH]total represents the total amount of hPAHwt added to each sample and [hPAH]sob 
the amount of hPAH present in the supernatant after NP deposition. Thus, EE corresponds to 
percentage of total protein that was encapsulated.  
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2.9. EUKARYOTIC CELL CULTURE 
The HEK293T and COS-7 cell lines were used to study hPAH-G46S and molecular chaperone 
interactions. The HepG2 cells were used for the evaluation of hPAHwt loaded NP. Cell cultures 
were grown at 37ºC with 5% CO2 in a humidified atmosphere in RPMI medium (Invitrogen) 
supplemented with 10% (v/v) of heat inactivated bovine serum (60ºC for 30 min) (FBS, 
Invitrogen), 100 U/ml penicillin, and 0.1 mg/mL streptomycin (Invitrogen) at a suitable 
concentration for cells to grow exponentially during the time of the assay. 
2.9.1. CELLULAR UPTAKE OF NP 
In the day before the assay, 5 mL of cell culture medium (2x105 cells/mL) were inoculated in 
T-flasks of 25 cm2 and incubated at 37ºC, with humidity control and 5% CO2 (Nuaire 
NU4750E). In the next day, culture medium was removed and 1 mL of fresh medium plus 500 
μL of hPAHwt NP formulation was added. After 1, 4, 6 and 16h of incubation, from each T-
flask the culture medium supernatant was collected. The cells were trypsinized with 500 μL of 
TripLE Express (Dissociation reagent, Life Technologies), centrifuged for 5 min, 100xg, at 4ºC, 
and washed with cold PBS buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM 
KCl, pH 7.4). The pellet was ressuspended in 100 μL of PBS buffer with 200 µM PMSF and 
cells were disrupted by passing the lysate repeatedly (≈ 20 times) through a fine needle. An 
aliquot of this suspension was stored and referred as the whole cell lysate. After centrifugation 
at 12800xg, for 10 min, at 4ºC, a lysate pellet and the lysate supernatant, constituting the 
intracellular medium, were obtained. Together, the (i) culture medium supernatant, the (ii) 
whole cell lysate, the (iii) lysate pellet and the (iv) lysate supernatant constitute the four 
samples that were further analysed by Western Blot after SDS-PAGE separation. 
2.9.2. TRANSFECTION ASSAYS 
A preliminary assay was made in order to optimize the ratio between pDNA and transfectant 
agent for hPAH-G46S expression in eukaryotic cells. For this, cells grown in 24-multiwell 
plates (Greiner-Bio One) to approximately 50-60% confluence, were transfected using 
branched PEI (25 kDa) at 1mg/mL in a 1:6 pDNA (pDNA hPAH-G46S) to PEI ratio (w/w). For 
controls assays, transfection with pGFP (Invitrogen) plasmid, using the same DNA amount 
and DNA to PEI ratio, and cells only with culture medium were also performed. After 14 h of 
transfection, the medium was changed and 48 hours post-transfection hPAH-G46S 
expression was detected by immunocytochemistry. 
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2.9.2.1. MOLECULAR CHAPERONES  
To prepare pDNA of the different molecular chaperones, E. coli TOP 10 competent cells were 
transformed according to standard methods and the DNA was prepared using the BioLine 
ISOLATE II Plasmid Mini Kit. For DNA quantification NanoDrop instrument (Thermo Scientific) 
was used and fluorescent signal was measured at l520 nm on a FLUOstar® Omega 
microplate reader. 
The HEK293T and COS-7 cells were seeded in 6-well plates and co-transfected with total 
amount of 750 ng DNA (375 μg for each construct: pEF-DEST51-G46S+STOP or pEF-
DEST51-molecular chaperone target) per 2x105 cells. Two transfectant agents were tested: 
PEI and LipofectamineÒ LTX in a 1:6 pDNA to transfectant agent ratio (w/w). The right amount 
of pDNA and transfectant agent in a 1:6 ratio and 500 μL of cell medium base was mixed 
together and incubated for 30 min at room temperature (RT), before being added to cell 
culture. After 14h hours of transfection, the medium was changed and 72 hours post-
transfection, co-expression was detected by western blot. As controls, cells expressing pGFP 
(Invitrogen) plasmid and cells only with culture medium were used. Some variables were 
tested during the several experiments, such as (i) the time of transfection, which initially was 
4h and then prolonged for 14h; and (ii) the time of post-transfection tested (48h, 72h and 96h). 
2.9.2.2. ASSAYS WITH THE TESTED COMPOUNDS 
The HEK293T and COS-7 cells were seeded in 12-well plates and transfected with a total 
amount of 750 μg DNA (pEF-DEST51-G46S+STOP) per 1x105 cells using PEI as transfectant 
agent in a 1:6 ratio. As described in 2.9.1.1, PEI, pDNA and cell medium base was mixed and 
incubated for 30 min, at RT, before being added to cell culture. After 14h of transfection, 
medium was supplemented with 50 μM (final concentration) of compound C2, C6 and C18 in 
1% DMSO, separately. A reinforcement of the same dose was added 48h after transfection. 
A parallel negative control with only 1% DMSO was included, as well as, cells expressing 
pGFP (Invitrogen) plasmid and cells only in culture medium. 
2.10. CO-IMMUNOPRECIPITATION ASSAYS 
For the co-immunoprecipitation assays (Co-IP), cells were harvested with TripLE Express 
(Dissociation reagent, Life Technologies), pelleted and lysed by three freeze–thaw cycles in 
50 μL of a low salt lysis buffer (50 mM Tris-HCl, pH 8.0, 1% NP-40) containing protease 
inhibitors (200 μM PMSF). The cell debris was removed by centrifugation at 12800 xg, during 
10 min, at 4 °C, and the supernatant was saved. An aliquot of 25 μL (whole cell lysate) was 
stored for further SDS-PAGEl analysis and the remaining 25 μL  was used for Co-IP. For this, 
100 μL (1 mg at 10 mg/mL) of SureBeads (BioRad) was washed 3x with 1 mL PBS-T (PBS, 
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0.1% Tween 20). A sample corresponding to 2.5 μg (1 mg/mL) of the anti-PAH mouse antibody 
(MAB5278, Millipore) was diluted in 200 μL of Tris-HCl 50 mM, pH 8.0 and incubated with the 
prepared magnetic beads for 10 min, at RT, with continuous stirring. The SureBeads were 
magnetized and washed 3x with 1 mL of PBS-T. The supernatant was discarded. The sample 
was added to the magnetic beads and incubated, with continuous stirring, for 1h, at RT. The 
Surebeads were again magnetized and washed as in the previous step. After spin down the 
tubes, to discard residual buffer, the sample was eluted by adding to the magnetic beads 25 
μL of 1x Laemmli buffers and incubation for 10 min, at 70ºC. The Surebeads were further 
magnetized and the eluted sample analysed by SDS-PAGE followed by western blot. 
2.11. IMMUNOCYTOCHEMISTRY ASSAYS 
For the immunocytochemistry assays, 48h post-transfection, HEK293T cells were rinsed twice 
with PBS containing 20mM glycine, and fixed for 30 min in a 4% (v/v) paraformaldehyde 
(Merck). After three washes with PBS, cells were permeabilized for 5 min with 0.1 % (v/v) 
Triton X-100 (Sigma-Aldrich) in PBS, washed two more times with PBS for 5 min and blocked 
with 1% (w/v) BSA in PBS for 30 min. After that, cells were incubated for 1 h with the anti-PAH 
mouse antibody (diluted 1:1000 in 1% (w/v) BSA in PBS). Cells were then washed three times 
with PBS for 5 min and incubated for 1 h with the FITC-conjugated anti-mouse IgG (GenScript) 
diluted 1:500 and washed three times again. 
Cell slides were mounted in ProLong® Gold antifade reagent with DAPI (Invitrogen) and their 
immunofluorescence was observed and recorded on an Axiovert 40CFL fluorescence 
microscope (Carl Zeiss) equipped with an Axiocam MRc5 (Carl Zeiss) camera. Images were 
processed with the software AxioVision Rel. 4.6.3 (Carl Zeiss). 
The same procedure was performed for HepG2 cells in order to visualize the cellular uptake 
of NPs, with an additional step for actin staining with Rhodamine phalloidin. After cell fixation, 
cells were permeabilized with 0,1% Triton X100 for 4 minutes and then cells were rinsed three 
times with 10mM PBS containing 20mM glycine at pH 7.4. The 6.6 mM phalloidin-TRITC (Life 
Technologies) solution in 10 mM PBS was added to the cells for 30 minutes at room 
temperature. After cells rinsed three times with 10 mM PBS containing 2 0mM glycine at pH 
7.4 and air dried, cell slides were mounted and observed as previously described. 
2.12. WESTERN BLOT ANALYSIS 
After electrophoretic separation the gel was equilibrated in Towbin buffer (25 mM Tris, 192 
mM glycine, 20% methanol, pH 8.3) for 15 min (168). For the transference process, a 
polyvinylidene difluoride (PVDF) membrane (Amersham Hybond-P;GE Healthcare), 
previously equilibrated according to manufacture instructions, and the semidry V20 transfer 
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system (Sci-Plas) were used. The transference was monitored through visualization of the 
NZYcolour protein marker II used as a control. After transfer the membrane was washed 3x 
with TBS buffer (140 mM NaCl, 20 mM Tris, pH 7.4), containing 0.1% Tween-20 (TBS-T), for 
5 min. To avoid unspecific binding, the membrane was incubated with blocking buffer (5% 
non-fat milk in TBS-T) for 3 h, at RT. Next, the membrane was washed 3x, 5 min each, with 
TBS-T and then incubated ON at 4ºC with primary antibody diluted in blocking buffer. The 
membrane was washed as in the previous step and then incubated with the secondary 
antibody, diluted in blocking buffer, during 3h at RT. After incubation, the membrane was once 
again washed 3x, for 5 min each, with TBS-T buffer. 
Blots were visualized with ECL Prime Western (GE Healthcare) at a ratio of 0.1 mL/cm2 of 
membrane and chemiluminescence was monitored on a ChemiDoc MP Imaging system 
(BioRad). 
For protein detection in NPs assays, the mouse monoclonal Anti-6His tag® antibody (Abcam) 
diluted 1:500 was used as the primary antibody and the anti-mouse IgG-HRP (W402B, 
Promega) was used as secondary antibody in a dilution of 1:2500. 
In the Co-IP assays the rabbit polyclonal Anti-6X His tag® antibody (Abcam) was used as the 
primary antibody and the goat anti-rabbit IgG-HRP antibody (BioRad) was used as the 
secondary antibody. Both antibodies were diluted at 1:1000.  
2.13. PAH ACTIVITY ASSAY 
For hPAHwt activity measurement within NPs, three conditions were established: (i) NPs in 
homogenized cells; (ii) NPs in SEC buffer; and (iii) NPs in culture medium. As control, the 
same conditions but with free hPAHwt and a hPAHwt solution at 4ºC were used. For the first 
condition HepG2 cells were homogeneized and then incubated with the NP and naked 
hPAHwt, separately, in a 96-well plate, at 37ºC, with shaking for 21h. 
After 1h, 2h, 3h, 4h 6h and 21h of incubation, the activity of naked and encapsulated 
hPAHwt was measured essentially as described by Gersting and collaborators (105) in the 
activated form (pre-incubation with L-Phe) using the natural fluorescence of L-Tyr and the 
microplate reader FLUOStar Omega equipped with an injector and a temperature controller. 
Briefly, the reaction mixture, performed in a 200 mL final volume (96 well microplate), 
contained 1 mM L-Phe, 0.1 M Na-Hepes, pH 7.0, 1080 U.mL-1 catalase, 5 mg of recombinant 
6xHis-hPAHwt (naked or nanoencapsulated) and 5 mM dithiothreitol DTT.  After 4 min of pre-
incubation, 100 μM ferrous ammonium sulphate was added to the mixture. After 2 min 
incubation, the reaction was started by the addition of 75 mM BH4. The L-Tyr production was 
continuously measured using fluorimetric detection (λexc= 260 nm and λem= 310 nm) and 
quantified using an adequate L-Tyr calibration curve (0.5 – 100 mM). The enzymatic reaction 
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was performed at a constant temperature of 25ºC and data acquired each 30 seconds 
during 15 minutes. 
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1. EFFECT OF 3HQS ON p.G46S AGGREGATION 
1.1. IN VITRO STUDIES 
1.1.1. EXPRESSION AND PURIFICATION OF MBP-hPAH-G46S 
For the in vitro studies of the p.G46S variant, the recombinant protein MBP-hPAH-G46S was 
produced in E. coli, at 28ºC, during 5 h, upon induction with 1 mM IPTG. 
In order to obtain a sample with a high purity degree, two chromatographic steps were used. 
The first purification procedure involved the use of affinity chromatography in order to purify 
the MBP-recombinant protein from the remaining proteins present in the soluble fraction using 
an amylose resin. The MBP tag present in the recombinant protein  has a high affinity to the 
amylose resin, and was further eluted using 10 mM maltose in the chromatographic eluent. 
The amylose purification profile is presented in Figure IV.1. 
 
	
FIGURE IV.1. Chromatographic profile of recombinant MBP-hPAH-G46S, obtained by affinity 
chromatography using an amylose resin. The peak corresponds to the elution of the MBP 
recombinant protein (51-77 mL). The dashed lines indicate the fractions collected and pooled 
for further purification by SEC. 
Upon purification of the MBP recombinant protein (fractions corresponding to the dashed lines 
in Figure IV.1), a second procedure using SEC was used to isolate the biological relevant 
tetramers The SEC chromatogram (presented in Figure IV.2) shows the obtained oligomeric 
profile. 
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FIGURE IV.2. Chromatographic profile of recombinant MBP-hPAH-G46S variant, obtained by 
size exclusion chromatography (SEC). Peak 1 correspond to aggregates and higher-order 
oligomeric forms (42-52 mL), peak 2 represents the tetrameric form (55-60 mL), peak 3 the 
dimeric form (62-65 mL) and peak 4 the maltose binding protein (MBP) (82-90 mL). The 
dashed lines indicate the fractions that were collected and utilized for further studies.  
The utilized chromatographic separation system allowed the isolation of different oligomeric 
forms of MBP-hPAHG46S, such as high-order oligomeric forms eluted in the column void 
volume (Figure IV.2, peak 1), the tetrameric forms (≈ 262 kDa; Figure IV.2, peak 2), dimeric 
forms (≈ 194 kDa; Figure IV.2, peak 3), and MBP (≈ 42 kDa; Figure IV.2, peak 4). As shown 
in figure IV.2, the MBP-hPAH-G46S variant was mainly expressed as soluble aggregates and 
only a small amount was present as. Interestingly, using the described expression as 
chromatographic conditions, monomeric forms of MBP-hPAH-G46S were not observed. After 
SEC, the fractions corresponding to the tetramers were collected (indicated by dashed lines) 
and concentrated until reach 7-9 mg/mL of protein concentration. 
As control of the purification procedures and protein integrity, samples of the isolated proteins 
collected from the amylose resin (Figure IV.3, line 1) and after SEC (Figure IV.3, line 2) were 
analysed through SDS-PAGE (Figure IV.3). 
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FIGURE IV.3. SDS-PAGE analysis of amylose and SEC purification of MBP-hPAH-G46S. (1) 
Sample from collected and pooled fractions from amylose chromatography (dashed line in 
Figure V.1), showing several proteins including MBP (≈46 kDa); (2) Sample from collected 
and pooled fractions after SEC (dashed lines in Figure V.2) showing a main band 
corresponding to the MBP-hPAH-G46S (≈ 96 kDa). (MM) Protein molecular mass marker 
(NzyColour protein marker II; Nyztech). 
1.1.2. EVALUATION OF FXA INHIBITION BY TESTED COMPOUNDS 
The library of 3HQs compounds synthesized by the Bioorganic group at iMed.ULisboa, were 
already tested for their ability to modulate the activity and stability of the hPAHwt (Raquel 
Lopes master thesis, under conclusion). As the above compounds demonstrated affinity for 
the hPAHwt and for some of them a stabilizing effect was also observed, we hypothesized 
that they might be capable of inhibiting hPAH-G46S aggregation in vitro. 
However, before proceed with G46S aggregation assays, an enzymatic assay in the presence 
of the compounds and a synthetic FXa substrate was performed in order to rule out any direct 
effect of the 3HQs derivatives upon the FXa activity. As FXa substrate the N-carbobenzyloxy-
glicyl-glicyl-arginyl-7-amino-4-methyl-coumarin (N-CBZ-Gly-Gly-Arg-AMC; I-1140; Bachem) 
was used. The protease FXa cleaves after the arginine (Arg) residue of the sequence Ile-
Glu/Asp-Gly-Arg releasing the AMC moiety of the substrate which presents fluorescence (λexc 
360 nm; λem 460 nm) which was measured along time. The obtained curves allowed 
calculating the enzymatic activity of FXa and concomitantly to infer for FXa inhibition. The 
lower the inhibition of FXa by the tested 3HQs compounds, the greater the fluorescence 
intensity detected, meaning that the compounds could be used to test for their effect on the 
aggregation of hPAH-G46S after MBP release by FXa. In Figure IV.4 is exemplified the 
obtained fluorescence in the presence of compounds with low, medium and high level of FXa 
inhibition. 
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FIGURE IV.4. Enzymatic assay to monitor the inhibition of FXa activity by the tested 3HQs 
derivatives. The figure shows three examples of assays performed in the absence () and 
presence of compounds showing different behaviour namely C2 () a non-inhibitor, C6 () 
mild inhibitor and C9 () a strong inhibitor. 
The FXa inhibition studies (presented in Table IV.1) showed that the majority of the tested 
compounds did not inhibit FXa activity. Only a slight degree of inhibition was found for C6 
(18% of inhibition) and C8 (15% of inhibition), while a more pronounced effect was detected 
for C4 (50% of inhibition) and C9 (73% of inhibition).  
TABLE IV.1 – Factor Xa activity in the absence and presence of tested 3HQ compounds at 
100 μM in two independent assays (each performed in triplicate). 
 Assay 1  Assay 2 
 Activity ± SD 
(AU.min-1) Inhibition (%)
a  Activity ± SD (AU.min-1) Inhibition (%)
a 
Control (1% DMSO) 296 0  367 0 
C2 426 ± 85.6 0  - - 
C4 147 ± 16.3 50  - - 
C6 242 ± 30.0 18  - - 
C8 253 ± 2.3 15  - - 
C9 81 ± 7.3 73  - - 
C10 - -  365 ± 53.8 1 
C11 - -  628 ± 19.0 0 
C12 - -  646 ± 38.8 0 
C14 - -  660 ± 35.3 0 
C15 - -  598 ± 64.4 0 
C16 - -  697 ± 32.1 0 
C17 - -  374 ± 20.8 0 
C18 - -  718 ± 44.4 0 
C19 - -  696 ± 20.4 0 
C20 - -  694 ± 25.4 0 
C21 - -  668 ± 11.8 0 
C22 - -  537 ± 54.4 0 
Notes: (SD) standard deviation. Activity values were determined as initial velocity (V0). a FXa protease 
inhibition in percentage was calculated by considered the activity in 1% DMSO and in the absence of 
compound  as 100%.  
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According to the obtained data only C4 and C9 should be excluded to proceed with the hPAG-
G46S aggregation assays and care should be taken when analysing the results obtained for 
C6 and C8. 
1.1.3. AGGREGATION ASSAYS 
As mentioned before, the MBP-hPAH-G46S provides an excellent system to evaluate the 
aggregation of the p.G46S variant as when the MBP fusion partner is removed, the hPAH-
G46S protein aggregates as non-amyloid like fibrils (169). In the hPAH-G46S aggregation 
studies two different control assays were performed (Figure IV.5): (i) a positive control reaction 
resulting from the MBP-hPAH-G46S cleavage by FXa in the presence of 1% DMSO and in 
the absence of compounds and; (ii) a negative control reaction including MBP-hPAH-G46S in 
the absence of FXa and compounds. For all the assays, aliquots of the aggregation reaction 
were withdrawn at the end (180 min) of the reaction and were analysed by SDS-PAGE to 
confirm the extent of MBP cleavage by FXa 
A 
 
 
B 
 
 
FIGURE IV.5. Control assays of the hPAH-G46S aggregation reaction followed by 
turbidimetry. (A) Positive control (PC) reaction resulting from the MBP-hPAH-G46S cleavage 
by FXa in the presence of 1% DMSO and in the absence of compounds. (B) Negative control 
(NC) reaction including MBP-hPAH-G46S in the absence of FXa and compounds. The SDS-
PAGE analysis at time 180 min of reaction is shown for the replicates of the assay. Data 
represents the mean±SD (error bars). 
Although the previous results of the evaluation of FXa inhibition immediately excluded 2 of the 
17 tested 3HQ compounds, they were considered in the hPAH-G46S aggregation assays. 
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However, it was known in advanced that absence of aggregation regarding any of those 2 
compounds (C4 and C9) and also C6 and C8, could be due to FXa inactivation and, 
consequently, to the non-cleavage of the MBP partner which keep the protein stable. 
The obtained results are exemplified in Figure V.6, for some of the tested compounds. 
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FIGURE IV.6.The hPAH-G46S aggregation reaction followed by turbidimetry in the presence 
of 3HQs derivatives, namely C2 (A), C6 (B) and C18 (C). (PC) Positive control reaction 
resulting from the MBP-hPAH-G46S cleavage by FXa in the presence of 1% DMSO and in 
the absence of compounds. The SDS-PAGE analysis at time 180 min of reaction is shown in 
the right panel for the replicates of the assay. Data represents the mean±SD (error bars). 
When following in vitro aggregation of the hPAH-G46S, the analysis of the obtained curves 
allow us to calculate the time needed to initiate aggregation (tlag or lag phase) as well as the 
rate of protein aggregation (k). The tlag and k obtained for the 17 compounds tested are shown 
in Table IV.2.  
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TABLE IV.2. Aggregation parameters of hPAH-G46S, followed by turbidimetry, in the absence 
and presence of tested 3HQ compounds at 100 μM. 
 Assay 1  Assay 2 
 tlag (min) 
k 
(AU.min-1) 
 
 
tlag phase 
(min) 
k 
(AU.min-1) 
Positive Control (1% 
DMSO) 35 0.040  60 0.019 
Negative Control ∞ -  ∞ - 
C2 43 0.098  - - 
C4 ∞ 0  - - 
C6 ∞ 0  - - 
C8 ∞ 0  - - 
C9 41 0.046  - - 
C10 ∞ 0  - - 
C11 - -  ∞ 0 
C12 - -  106 6.5x10-6 
C14 - -  55 0.021 
C15 - -  104 2.4x10-5 
C16 - -  ∞ 0 
C17 - -  94 0.0080 
C18 - -  ∞ 0.0013 
C19 - -  ∞ 0 
C20 - -  ND ND 
C21 - -  ND ND 
C22 - -  ND ND 
Notes: (k) aggregation rate, correspond to the slope of each curve; (tlag) lag phase. Both parameters 
were calculated through a plateau followed by one phase association equation. (ND) Not determined. 
(AU) arbitrary units. 
 
In the positive control (PC; Figure IV.5.A), the cleavage of MBP-hPAH-G46S fusion protein by 
FXa leaded to the aggregation of the unstable hPAH-G46S mutant enzyme with a  tlag of 35 
min (Table IV.2), while in the negative control (NC; Figure IV.5.B), in the absence of FXa, no 
increase in absorbance was observed (tlag ∞) meaning that there was no protein aggregation. 
The hPAH-G46S aggregation profile in presence of C2 (FigureI IV.6.A) is similar to the PC 
with a tlag of  43 min which means that C2 is a poor aggregation inhibitor. On the contrary, C6 
(Figure IV.6.B) and C18 (Figure IV.6.C) are strong and mild aggregation inhibitors, 
respectively, as the hPAH-G46S aggregation profile has no absorbance increasing with tlag 
impossible to be calculated (∞; Table IV.2).  
As such, according to the obtained tlag and k (shown in Table IV.2) from the 17 compounds 
tested, we were able to group them in three different categories according to the obtained 
aggregation parameters, namely strong (C6, C8, C10, C16, C19); mild (C18, C12, C15, C17); 
and poor (C2, C9, C14) inhibitors. Regarding C4 and C9, conclusions cannot be stablished 
as the compounds showed an inhibitory activity against FXa.  
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1.2. IN CELLULO STUDIES 
For the in cellulo studies of hPAH-G46S aggregation, C2, C6 and C18 were the selected 
compounds, as they showed, in vitro, three different outstand behaviors. These assays were 
performed in HEK293T cells once they do not express the hPAH protein constitutively.  
A preliminary assay was performed in order to optimize the transfection conditions and the 
immunocytochemistry procedure. In these assays the HEK293T cells were transfected with 
different amounts of the pG46S expression construct namely, 143 ng, 285 ng and; 570 ng. 
Non-transfected cells were used as control. 
As shown in figure IV.7, the HEK293T cells were successfully transfected with the pG46S 
expression construct and as expected, protein expression was dependent of the amount of 
the DNA used, being 570 ng the optimal quantity to express the p.G46S variant in HEK293T 
cells (Figure IV.7.D). 
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FIGURE IV.7. Transfection efficiency of HEK293T cells with pG46S constructs evaluated by 
Immunocytochemistry analysis. Cells were transfected using different amounts of plasmid 
pG46S: (B) 142 ng; (C) 286 ng and (D) 572 ng. Non-transfected cells were used as control 
(A). 
Interestingly, while performing the preliminary optimization of the immunocytochemistry 
assay, it was possible to observe that the hPAH-G46S when expressed in mammalian cells, 
such as HEK293T, seemed to be aggregated as their expression pattern is not homogenous 
but appeared as intracellular fluorescent dots. These data corroborated the data obtained in 
vitro (MBP-hPAH-G46Saggregation assays) indicating that also in mammalian cells the 
protein tends to aggregate.  
This was definitely a good point start that led us to evaluate in cellulo the modulation capacity 
of C2, C6 and C18 compounds regarding the hPAH-G46S aggregation profile. For the 
immunocytochemistry assay, the hPAH-G46S mutant protein (positive control) and the 
hPAHwt protein (negative control) were expressed, separately, in HEK293T cells using the 
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previous optimized conditions. Cells expressing hPAH-G46S were incubated with 50 μM of 
each compound in 1% DMSO and also with 1% DMSO, as a blank control. 
As shown in Figure IV.8.1 and Figure IV.8.2, HEK293T were successfully transfected as they 
expressed either the hPAHwt (Figure IV.8.1.C) or hPAH-G46S (Figure IV.8.1D and Figure 
IV.8.2 E to H). 
Analysis of the immunocytochemistry assays presented in Figure IV.8.1 clearly showed that 
the hPAHwt and hPAH-G46S proteins have different patterns of cell expression. In fact,  the 
hPAHwt it is uniformly expressed within HEK293T cells (Figure IV.8.1.C) while the p.G46S 
variant shows an uneven pattern of expression observed by intracellular fluorescent dots 
(Figure IV.8.1.D), suggesting protein aggregation. 
 
FIGURE IV.8.1. In cellulo evaluation of hPAH-G46S aggregation profile in HEK293T cells, 
after incubation with 50 μM of 3HQs derivatives in 1% DMSO. The assay controls included 
control cells (A), GFP protein expression (B), hPAHwt protein expression (C) and hPAH-G46S 
protein expression (D) cells incubated with 1% DMSO (E). The green dots indicate protein 
aggregation. 
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FIGURE IV.8.2. In cellulo evaluation of hPAH-G46S aggregation profile in HEK293T cells, 
after incubation with 50 μM of 3HQs derivatives in 1% DMSO. Cells incubated with 1% DMSO 
(E), C2 (F), C6 (G) and C18 (H).  
 
Regarding the hPAH-G46S expression in presence of the tested compounds, and as expected 
from the in vitro aggregation assays, only with C6 (Figure IV.8.2.G) and C18 (Figure IV.8.2.H) 
a reversion of the expression pattern of p.G46S is altered with no visible  intracellular 
fluorescent dots, suggesting that protein aggregation was reverted by these 3HQs derivatives. 
However, when observing the expression pattern of hPAH-G46S in presence of C2 (Figure 
IV.8.2.F) the intracellular fluorescent dots are still present corroborating the in vitro 
aggregation assay. In fact in this assay the C2 3HQ derivative was unable to inhibit 
aggregation of the hPAH-G46S (Figure IV.8.2.F) Interestingly, cells expressing the hPAH-
G46S and incubated in the presence of 1% DMSO, although presenting an image 
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characteristic of aggregated protein, the fluorescent green dots were less intense than 
expected (Figure IV.8.2.E). 
2. STUDIES OF hPAH-G46S AND MOLECULAR CHAPERONE INTERACTIONS 
2.1. OPTIMIZATION ASSAYS 
It is known from previous expression studies in eukaryotic cell lines, that the immunoreactive 
level of the p.G46S variant is very low (~3%). It has been hypothesized that the variant protein 
will be rapidly degraded by the cell protein quality control system, thus leading to low cellular 
steady-state levels. As the mechanism by which this degradation occurs is unknown, the aim 
of this experiment was to co-express, in eukaryotic cell lines, the p.G46S variant protein and 
key molecular chaperones, which, according to literature, might be involved in the proteostasis 
network that handles the p.G46S hPAH variant. Following co-expression, a Co-IP technique 
will allow inferring for potential interactions among the p.G46S and target molecular 
chaperones.  
The antibodies used for Co-IP took advantage of the presence of a 6xHis tag in the expressed 
molecular chaperones and first several assays were performed in order to optimize this 
experimental approach namely: (i) different eukaryotic cell lines; (ii) transfection reagent; (iii) 
time of contact between cells and transfection reagents and; (iv) incubation time. 
Regarding the cell lines, throughout the process two different cell lines were used, HEK293T 
cells (as they do not constitutively express PAH) and COS-7 cells (as they have been used in 
several hPAH expression studies). The cells were transfected with the DNA constructs 
expressing the p.G46S and molecular chaperones either isolated or simultaneously (co-
transfection).  
First we aimed to confirm cell expression of both proteins, separately or together. When using 
COS cells, by increasing contact time between cells and transfection reagents from 4 to 14 h, 
and rising the incubation time from 48 to 72 h, it was possible to obtain a slight signal of the 
p.G46S protein (Figure IV.9.I), by western blot analysis, but no signal of molecular chaperone 
(Figure IV.9.II).  
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FIGURE IV.9. Western blot analysis of hPAH-G46S (I) and the molecular chaperone 6xHis-
HSPAB1 (II) expressed in COS-7 cells. Cells were transfected using PEI, incubated for 48 h 
and 72 h and different cellular fractions were analyzed: total lysate (A), supernatant (B) and 
pellet (D). The 6xHis-hPAHwt was used as control (C). The anti-hPAH and anti 6xHis primary 
antibodies were used in I and II respectively. 
Facing these results we hypothesized that the obtained data could be a result of poor 
transfection efficiency. So, in an attempt to increase transfection efficiency and thus protein 
expression, the transfection reagent was changed from PEI to lipofectamine®. This assay was 
performed in HEK293T and COS-7 cells, maintaining the 72 h of incubation. However, the use 
of lipofectamine® did not significantly improve protein expression (data not shown), so the use 
of PEI was maintained for economic reasons.  
As the result of the optimization assays a contact time between cells and transfection reagents 
of 14 h and an incubation time for protein expression of 72 h was chosen for co-transfection 
(Figure IV.10). The same results were obtained with both HEK293T and COS-7 cells (results 
not shown), so either of this cell lines can be used in this assay.   
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FIGURE IV.10 – Western blot analysis of the molecular chaperone 6xHis-Hsp90AB1 (I) and 
hPAH-G46S (II) in transfected and co-transfected COS-7 cells after 72h incubation. The total 
cell lysate (A)  and the supernatant fraction were analysed.  The 6xHis-hPAHwt was used as 
control (C). Immunoblot was done against Hsp90AB1 (1) and G46S (2). The anti 6xHis and 
anti-hPAH primary antibodies were used in I and II respectively. The band corresponding to 
the molecular chaperone (I) and the p.G46S (II) in the co-transfection assay are indicated by 
an arrow. 
Interestingly, the band corresponding to the Hsp90AB1 (≈ 90 kDa; Table IV.1) was only 
observed in the co-transfection assay (Figure IV.10.I).  
Considering the obtained data the study of hPAH-G46S/molecular chaperones interactions 
through Co-IP was then initiated. 
2.2. CO-IMMUNOPRECIPITATION ASSAYS  
The molecular chaperones firstly selected for testing were chosen based on their described 
main role (Table III.1) and included three members of the HSP70 family (HspA8; HspA2 and 
HspH1) and one member of the HSP90 family (Hsp90AB1). The SQTM1 protein, a member 
of the sequestosome-1, was also selected as it has been described as being involved in the 
degradation pathway of polyubiquitin-containing bodies. 
Hence, HEK293T cells were co-transfected with the DNA constructs expressing the p.G46S 
variant and one of the molecular chaperones, and incubated for 72 h. Preliminary data from 
the CoIP experiments (Figure IV.11) shown unspecific signals for each of the molecular 
chaperones tested with no clear band with the expected MM (indicated by an arrow in Figure 
IV.11). However, each of the analysed Co-IP seemed to present a different pattern which may 
indicate some differences in the hPAH-G46S/molecular chaperone interactions. However, 
further assays are needed to elucidate the above mentioned phenomenon. 
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FIGURE IV.11 – Western blot analysis of hPAH-G46S/molecular chaperones interactions 
using Co-IP upon co-expression in HEK293T cells. The molecular chaperones tested included 
Hsp90AB1, HspA8, HspA2, HspH1 and SQSTM1. The anti-hPAH antibody was used in the 
immunoprecipitation step and for the western blot analysis an anti- 6xHis was used as the 
primary antibody. 
3. IN CELLULO EVALUATION OF hPAHwt LOADED NANOPARTICLES 
When formulating a protein aiming development of ERT an optimized balance between 
functionality and the gain of thermodynamic stability should always be sought to attain the 
best protein fitness possible. One of the main strategies applied to pharmaceutical protein 
stabilization, include their immobilization into biodegradable carriers, such as CS NP.  
Following the successful incorporation of hPAHwt in CS NP with the in vitro maintenance of 
the enzymatic activity, L-Phe activation, thermostability and protein conformation, our 
research group now aimed to assess the NP cellular uptake, as well as, to evaluate the activity 
of hPAHwt loaded CS NP in the cellular fractions. This will allow us to stablish if the CS NP 
are able to stabilize the enzyme in cellulo and provide a potential safe and effective nano drug 
delivery system (nano-DDS). 
3.1. EXPRESSION AND PURIFICATION OF hPAHwt 
The recombinant protein hPAHwt was produced in E. coli, at 37ºC during 4 h of induction with 
1 mM IPTG. Under these conditions, the overexpressed recombinant protein was mostly 
recovered in the soluble fraction (results not shown). 
In order to have a sample with high purity grade, which is necessary to the hPAHwt assays, 
two chromatographic procedures were used namely an IMAC using a Ni-NTA resin and SEC 
to isolate the biological relevant tetrameric form.  
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The IMAC purification profile of hPAHwt is represented in figure IV.12. The soluble fraction of 
the lysate was washed with increasing concentrations of imidazole solutions in order to purify 
the protein of interest, As observed in Figure IV.12 (line 2 to 6) the bacterial proteins present 
in the soluble fraction were eluted during the washing steps.  
 
 
FIGURE IV.12 – SDS-PAGE analysis of IMAC purification profile of hPAHwt. (1) Flow-through; 
Washing steps using 6xHis lysis buffer containing 20 mM imidazole (2 and 3),50 mM imidazole 
(4 and 5) and 75 mM imidazole (6). The recombinant 6xHis-hPAHwt protein was eluted using 
6xHis lysis buffer containing 250 mM imidazole (7 to 9). (MM) Prestained protein molecular 
weight marker (NzyColour protein marker II, Nyztech). The MM of the recombinant 6xHis 
hPAHwt is indicated (≈ 54 kDa). 
As the IMAC purification is a common procedure in the Met&Gen group lab, the elution 
scheme (Figure IV.12; lines 7 to 9) had been optimized in previous work. Eluting the protein 
with 3x500 µL of 250 mM imidazole buffer is the optimum elution scheme to obtain an 
adequate volume (1.5 mL) to be immediately injected in the SEC column (5 mL loop) without 
further manipulations. Through SEC, the tetrameric form of the hPAHwt protein was isolated 
(Figure IV.13, peak 3). 
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FIGURE IV.13. Chromatographic profile of recombinant hPAHwt, obtained by size exclusion 
chromatography (SEC). Peak 1 represents higher-order oligomeric forms (44-47 mL), peak 2 
represents the octameric form (52-56 mL), peak 3 the tetramer (56-66 mL) and peak 4 the 
dimer (69-71 mL).  
The developed chromatographic separation system allowed the isolation of different 
oligomeric forms of hPAHwt, such as high-order oligomeric forms eluted in the column void 
volume (Figure IV.13, peak 1), octamers (≈ 440 kDa; Figure IV.13, peak 2), tetramers (≈ 220 
kDa; Figure IV.13, peak 3) and dimers (≈ 110 kDa; Figure IV.13, peak 4). As shown in the 
chromatogram presented in Figure IV.13, the hPAHwt was mainly purified and tetramers 
(60.4%), with a small percentage of dimers (6.5%), octamers (22.4%) and aggregates 
(10.7%). Using these chromatographic conditions, it was not possible to detect any peak 
corresponding to the monomeric form of hPAHwt. After SEC, the fractions corresponding to 
the tetramers were collected (Figure IV.13; dashed lines), pooled and concentrated until reach 
7-9 mg/mL of protein concentration. 
3.2. PROPERTIES OF NANO ENCAPSULATED hPAHwt 
After the nanoencapsulation procedure, using the controlled conditions previously optimized 
(CS:TPP mass ratio of 5:1, initial CS pH 5.5), the system was characterized regarding a 
hPAHwt loading of 250 μg/mL.  
Through the DLS technique, mean size of empty and loaded CS:TPP nanoparticles were 
determined and are presented in Table IV.3. Mean size was slightly increased in loaded NP 
without extensive PI destabilization (Table IV.3). In terms of zeta potential either the empty or 
the loaded CS-NP have a positive value of 25 ± 1 mV and 20 ± 2 mV, respectively, indicating 
that after protein encapsulation the surface charge remains similar. 
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Regarding encapsulation efficiency (E.E.), a high incorporation efficiency of 82 ± 2 (% w/w) 
was observed and was also expected, due to the previous work developed for optimization of 
formulation conditions. 
 
Table IV.3 – Characteristics of empty and loaded chitosan nanoparticles 
 E.E.  
(% w/w) 
Zeta Potential 
(+mV) 
Mean Size  
(µm) 
P.I. 
Empty 
Nanoparticles 
N.A. +25 ± 1 263 ± 3 0.239 ± 0.005 
Loaded 
Nanoparticles(a) 
82 ± 2 +20 ± 2 290 ± 4 0.186 ± 0.012 
Notes: (P.I.) polydispersity index; (E.E.) encapsulation efficiency; (N.A.) Not Applicable. The data 
represent the mean and SD of three independent assays. (a)Loading of 250 μg/mL hPAHwt. 
 
3.3. EVALUATION OF hPAHwt CONTENT AND FUNCTION IN DIFFERENT 
CELLULAR FRACTIONS 
The CS:TPP NP loaded with hPAHwt where incubated with hepatocyte derived HepG2 cells 
in order to evaluate the NP internalization (cellular uptake) and the protein content in different 
cellular fractions, namelly: (i) culture medium supernatant; (ii) whole cell lysate; (iii) lysate 
pellet and; (iv) lysate supernatant. 
The aim was to build a cellular model to evaluate if cellular uptake of NPs occurred and 
concomitantly the cell could gain the capacity to metabolize L-Phe into L-Tyr through the 
hydroxylation reaction.  
The content of the hPAHwt protein loaded in the NP was evaluated in different cellular 
fractions for different times of incubation, at 37ºC. In Figure IV.14 the western blot analysis of 
the cellular fractions after 1 h, 6 h and 16 h of incubation with CS-NP-hPAHwt is shown.  
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FIGURE IV.14 – Western Blot analysis of 6xHis hPAHwt in different cellular fractions of HepG2 
after  cell incubation with NP-CS-hPAHwt for 1 h, 6 h and 16h. (A) Culture medium 
supernatant; (B) whole cell lysate; (E) lysate supernatant and; (F) lysate pellet. The 6xHis 
hPAHwt was used as control (C). The anti- 6xHis was used as the primary antibody 
The obtained data indicate that the 6xHis hPAHwt protein is present in the culture medium 
supernatant till 16 h incubation, at 37ºC, demonstrating that the protein is maintained (and not 
degraded) during this time period (Figure IV.14.A). However, only after 16 h of contact it was 
possible to recover the protein in the whole cell lysate (Figure IV.14.B) and in the lysate pellet 
(Figure IV.14.F), but never in the supernatant of the cell lysate (Figure IV.14.E). These data 
indicate that the free hPAHwt and/or the encapsulated form is associated to the cellular 
membrane. However, the question whether the CS-NPs are outside or inside cellular 
membrane remains to be clarified. 
The absence of PAH in the lysate supernatant observed in this assay (Figure IV.14.E) can be 
justified by different factors, such as, the need for optimizing the cell culture conditions, more 
specifically, temperature and/or time of incubation. Another aspect that must be taken into 
account is the internalization pathway used by the CS-NP. NPs are known to be internalized 
by the cells through endocytosis during long periods of incubation and, thus latter on they are 
found in organelles associated to membranes and, only occasionally, free in cytoplasm (170). 
To clarify the hypothesis of whether the protein, although associated to cell membranes, would 
be inside or outside the cell, immunocytochemistry assays were performed. However, and as 
shown in Figure IV.15, the results were inconclusive. We were able to confirm that after 16 h 
of incubation, the CS-NP-hPAHwt were indeed associated to cell membrane, seen by the 
green fluorescent dots along the cell membrane marked in red (Figure IV.15.B), but their exact 
location is still unknown. 
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FIGURE IV.15 – Immunocytochemistry assays in HepG2 cells cultured for 16 h, at 37ºC, in 
the absence (A) and presence of hPAHwt loaded CS-N P (B). Immunofluorescence 
microscopy was performed by using anti-mouse FITC-conjugated secondary antibody (green) 
for hPAH. Nuclei and actin ere counterstained with Dapi (blue) and Phalloidin (red). 
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3.4. STABILITY OF hPAH ACTIVITY 
The previous assays showed that the 6xHis hPAH loaded in CS-NP is stable until 16 h of 
incubation, at 37ºC, when in contact with HepG2 cells. However, the functionality of this 
protein was still unknown. To evaluate if the biological function of hPAHwt was preserved in 
the CS-NP formulation the hPAH activity was determined, at different incubation times, in both 
the cell culture and in total cell lysate. Appropriate control assays (naked hPAHwt in the same 
assay conditions) were also performed.  
To date, measurement of hPAH activity is routinely performed in our lab, using an end point 
assay and a standard reaction mixture containing the enzyme, Fe2+, L-Phe and BH4.  The L-
Tyr production is further determined by HPLC with a time-consuming chromatographic 
separation of substrate and product. The implementation in our laboratories of the 
fluorescence-based multi-well assay, developed by Gersting et al (105), has given rise to the 
possibility of evaluating hPAH activity more rapidly, but as precisely and accurately as the 
standard methods. This technique uses a fluorescence detection device with an integrated 
injection system. The differences in the fluorescence properties of the aromatic amino acids 
L-Phe and L-Tyr, such as emission and excitation wavelengths as well as the quantum yield, 
allow spectral separation of these substances even in a mixed solution. To confirm spectral 
separation of the two substances, a calibration curve was determined through detection of 
fluorescence signal intensities of varying L-Tyr concentrations in the presence of 1 mM L-Phe 
(Figure IV.16) and as function of increasing L-Phe concentrations (results not shown). The 
curve showed linear correlation, so, detection of L-Tyr was unaffected by the various L-Phe 
concentrations. 
 
 
Figure IV.16 – Fluorescence intensity of L-Tyr solutions (0 – 150 µM) in the presence of 1 mM 
L-Phe. Values are given as the mean ± SD of three independent measurements. 
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Using the above fluorescence-based multi-well assay the hPAH activity was determined after 
1, 2, 4 and 21h incubation, at 37 ºC, in different mediums namely, SEC buffer, culture medium 
and cell homogenate. As control the naked hPAHwt was also studied in the same conditions. 
The obtained activities were compared with the values obtained for the hPAHwt maintained 
at 4ºC, which were considered 100%. The obtained data are presented in Figure IV.17. 
 
 
Figure IV.17 – Residual enzyme activity determined after 1 (¢), 2 (¢), 4 (¢) and 21 h (¢) 
incubation of naked hPAHwt and hPAHwt loaded CS-NP, at 37ºC, in different mediums. The 
enzyme activity of hPAHwt maintained at 4ºC was considered 100%. The data represent the 
mean and SD of two independent assays.  
After 21 h incubation, in all the conditions tested the residual enzyme activity was below 29%. 
For the other tested conditions no significant differences were observed among the naked and 
encapsulated hPAHwt, except when the assay was performed in culture medium. In this 
condition, and when compared with the naked hPAH, the encapsulated hPAHwt seemed to 
be protected resulting in a higher activity for the 1, 2 and 4 h incubation tested.   
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CHAPTER V • CONCLUSION AND FUTURE 
PERSPECTIVES 
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The search for an effective treatment for the severe forms of phenylketonuria, a 
conformational disorder with loss-of-function, led us to explore distinct approaches that per se 
or in combination could treat the most severe clinical phenotypes that currently do not have 
an alternative treatment other than the life-long burdensome restrictive diet which has been 
associated with and long term decline in executive function. 
This work has contributed to: (i) hint a new class of pharmacological chaperones acting on the 
aggregation of the severe p.G46S variant; (ii) optimize experimental conditions for further 
studies aiming the elucidation of the proteostasis network pathways involved in the 
degradation of variant hPAH proteins that ultimately can lead to the identification of 
proteostasis regulators as a new class of small molecules for the treatment of PKU and; finally 
(iii) confirm that loaded CS nanoparticles, previously developed by the research group, are a 
potential drug delivery system (DDS) for further studies aiming a novel PKU treatment 
approach by enzyme replacement therapy. 
The in vitro model of the aggregation-prone p.G46S variant, allowed the identification of small 
molecular weight compounds inhibiting p.G46S aggregation (C6 e C18). These compounds 
belong to an in-house rationally-designed compound library of 22 3HQ derivatives and were 
designed (and synthesized) by the Bioorganic Group (coordinated by Prof. Pedro Góis; 
iMed.ULisboa) to specifically interact with the hPAH protein by incorporating in their structure 
the substrate L-Phe (to confer specificity) and the pharmacophore 3-hydroxyquinolin-2(1H)-
one (3HQ) (by its ability to complex iron). The 3HQ derivatives C6 and C18 not only inhibited 
p.G46S in vitro aggregation but also in cellulo and are promising compounds to be used 
scaffolds for further structure refinement. However, the mechanism of binding is still unknown 
but taking into consideration of previous data obtained by our research group showing that 
compounds that inhibit the p.G46S aggregation also inhibit the aggregation of the hPAH N-
terminal regulatory domain (171) we hypothesize that C6 and C18 will probably have a similar 
mechanism of binding to the hPAH regulatory domain. To confirm our hypothesis these 
molecules will be soon sent to Professor Wyatt Yue (University of Oxford), under a 
collaborative project, to perform co-crystallization assays (C6 and C18 and the N-terminal 
regulatory domain). Moreover, the identification of these modulators could lead to a new class 
of pharmacological chaperones that could be further used to study synergisms between the 
use of proteostasis regulators and pharmacological chaperones. 
In conformational disorders with loss-of-function the normal balance between folding and 
degradation machineries (proteostasis) is displaced towards the accelerated degradation of 
the misfolded protein due to their decreased stability and high tendency to aggregate. 
Therefore, small molecules modulating, not only the conformation (pharmacological 
chaperones), but also the interactions of misfolded proteins with molecular chaperones 
(proteostasis regulators), will enhance the concentration and/or location of the target proteins 
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thus contributing to alleviate disease pathogenesis. As such this project aimed to study in 
HEK293T cells (as they not express hPAH constitutively), the p.G46S interactions with 
proteins of the folding and the cell protein quality control system as putative proteostasis 
therapeutic targets. Different interaction patterns, between p.G46S and the tested molecular 
chaperones (Hsp90AB1, HspA8, HspA2, HspH1 and SQSTM1), were observed. Although no 
conclusive results came up, these experiments allowed the optimization of the experimental 
conditions, which might open doors to further studies using the modulation of proteostasis 
regulators aiming the cellular rescue of variant hPAH proteins. 
Finally, the previously developed nano-DDS (CS-NP loaded with hPAHwt) was characterized 
and evaluated. At a first evaluation the CS-NPs did not seem to be uptaked by cells. Although, 
the immunocytochemistry assay showed that they might be associated to the cell membrane, 
it is still unclear if they are associated to internal cell membrane structures. As such, confocal 
microscopy assays should be performed in order to clearly assess the cellular localization of 
the developed hPAHwt loaded CS-NPs. Interestingly, our preliminary assays, regarding a 
protective effect of CS-NPs, showed that in fact the nanoencapsulated hPAHwt presented a 
higher activity (after 4 h incubation in culture medium, at 37°C) than the naked protein (in the 
same experimental conditions). In terms of desirable effects of the DDS, the protective effect 
is probably more important when compared to NPs cell internalization, once our main goal is 
to have a L-Phe degradation capacity (hPAH enzymatic activity) but not necessarily occurring 
inside the cell (hepatocyte). Although this experimental approach showed good perspectives, 
in order to achieve an accurate point of star, a higher number of assays (n) are needed.  
In conclusion, this work allowed the identification of small molecular weight compounds 
modulators for severe forms of PKU, the optimization of a model to identify proteostasis 
regulators involved in loss-of-function disorders, as well as, a vision of a possible synergic 
approach with the use of proteostasis regulators and pharmacological chaperones and, finally, 
optimized techniques to continue developing strategies to move forward with the enzyme 
replacement therapy approach. 
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APPENDIX 
 
1. Vector used for expression of hPAHwt 
 
 
Figure III.1 – Map and features of pTrcHis vector (Invitrogen) (172). 
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2. Vector used for the expression of hPAH-G46S fusion protein 
 
  
Figure III.2 – Map and features of pMAL-c2X (England BioLabs). Unique restriction sites are 
indicated (173). 
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3. Vector used for the expression of molecular chaperone in eukariotic systems. 
 
 
 
Figure III.3 – Map and features of pEF-DEST51 Gateway™ Vector (156). 
 
 
 
Figure III.4 – The Gateway™ Recombination system (157). 
 
